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Liver cancer is a global health problem.  Over the last 20 years, despite the advancement 
in anti-cancer therapies, liver cancer-related death increased by as much as 50%. Liver 
cancer is a typical inflammation-associated cancer; with more than 90 % of cases arising 
in the context of hepatic injury and inflammation. Interestingly, the pleiotropic molecule, 
TGFB1, lies in the center of this inflammatory cascade. Increased TGFB1 expression is 
observed in liver cancer patients, yet a conclusive role for the molecule in liver cancer is 
lacking.  TGFB1 was first identified as an inhibitor of cell cycle progression, thus is 
known as a tumor suppressor. More recent studies uncovered pro-tumor capabilities of 
the molecule, such as to induce epithelial-to-mesenchymal transition and to orchestrate 
the tumor microenvironment. In this study, by using a combination of zebrafish cancer 
models and human liver disease samples, roles of TGFB1 on tumor microenvironment 
and during liver cancer initiation were examined in a tripartite study.  
 
1) Stimulation of hepatocarcinogenesis by neutrophils upon induction of oncogenic kras 
expression in transgenic zebrafish 
Chronic inflammation is a major etiological factor for hepatocellular carcinoma (HCC), 
but how immune cells respond in the initiation of hepatocarcinogenesis remains 
uncharacterized. The first part of the study aimed to investigate the response and roles of 
neutrophils in early hepatocarcinogenesis. When hepatocarcinogenesis was induced by 
oncogenic krasV12-expression, a rapid recruitment of neutrophils to oncogenic livers was 
observed. Stimulation of neutrophils resulted in further increases of neutrophils in 
oncogenic livers, liver size and tumor severity, while inhibition of neutrophils caused 
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decreases of liver-associated neutrophils and liver size. Both oncogenic hepatocytes and 
tumor-associated neutrophils (TANs) were isolated via fluorescence-activated cell sorting. 
Molecular analyses indicated a pro-inflammatory microenvironment, as marked by 
increased tgfb1a expression in krasV12-expressing hepatocytes and a loss of anti-tumor 
activities in TANs. Depletion of Tgfb1 significantly reduced the number of TANs and the 
size of oncogenic liver, establishing Tgfb1 as a pro-tumor inducer for TAN in zebrafish.  
 
2) Cortisol promotes gender disparity in hepatocellular carcinoma by activating tumor 
associated neutrophils and macrophages in zebrafish 
HCC occurs more frequently and aggressively in men than women. Although sex 
hormones have been implicated in the gender disparity, the contribution of other 
hormones is largely unknown. The second study aimed to investigate the contribution of 
TANs or tumor associated macrophages (TAMs) in gender disparity in HCC, and its 
underlying regulating mechanism. Accelerated liver tumor progression was observed in 
krasV12-expressing male zebrafish and male liver tumors were also more heavily 
infiltrated with TANs and TAMs both of which showed molecular expression for pro-
tumor activities and promoted liver tumor progression. Cortisol was found to be 
predominantly produced in male liver tumors and induced tgfb1 expression in 
hepatocytes for attracting TANs and TAMs. Inhibition of cortisol signaling in male 
zebrafish or increase of cortisol level in female zebrafish could decrease or increase the 
numbers of TANs and TAMs accordingly, accompanied with the changes of molecular 
expression to decrease or increase pro-tumor activities. The role of cortisol in promotion 
of liver tumors was further validated by increase of cortisol level in females and 
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inhibition of cortisol signaling in males. Hence, a predominant increase of cortisol 
production caused more robust pro-tumor behaviors in TANs and TAMs, resulting in 
male prominence of HCC. Interestingly, the finding of higher levels of cortisol and 
TGFB1 in males was also confirmed in human pre-HCC and HCC samples and there was 
a positive correlation of cortisol level of TGFB1 expression inhuman patients.  
 
3) Non-alcoholic steatohepatitis induced TGFB1 overexpression causes both 
hepatocellular carcinoma and cholangiocarcinoma 
Patients with non-alcoholic steatohepatitis (NASH) are at high risk for both HCC and 
cholangiocarcinoma (CCA), yet the underlying molecular mechanism promoting the 
transition is unclear. In the third study, we demonstrated the driving role of NASH-
induced Tgfb1 in both HCC and CCA in the zebrafish model. With a diet-induced 
zebrafish NASH model, elevated level of the satiety hormone, leptin, induced 
overexpression of Tgfb1 via a Stat3-dependent mechanism in hepatocytes. By generation 
of an inducible tgfb1a transgenic zebrafish line, we found that chronic and high level of 
tgfb1a induction in hepatocytes caused not only HCC but also CCA. Molecularly, 
oncogenicity of Tgfb1 is dependent on the switch of a dominant activated signaling 
pathway from Smad to Erk pathway, which was validated in human liver disease patient 
samples. These findings pinpointed the definitive role of Tgfb1 as both a switch of liver 
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1.1 Introduction to liver cancer 
1.1.1  Incidence and epidemiology of liver cancer 
Human liver cancer is the fifth most common cancer and the second most common cause 
of cancer related death in the world, with a five year survival rate of only 10% (Iakova, 
Timchenko, & Timchenko, 2011).  These malignancies are the second most common 
cause of cancer-related death after lung cancer and one of the three types of solid tumors 
that saw an increased incidence and mortality globally.  Most of the primary liver cancers 
are of epithelial cell origin, arising mainly from hepatocytes or intrahepatic bile duct cells 
(Srivatanakul, Sriplung, & Deerasamee, 2004). Cancer of the hepatocyte lineage, more 
commonly known as hepatocellular carcinoma (HCC), is the most prevalent malignancy 
of the liver, accounting for 83% of all cases. Neoplasia of biliary cells, CCA, although far 
less rampant than HCC, is the 2nd most fatal liver cancer (Srivatanakul et al., 2004). 
Global incidence of new liver cancer cases is estimated to be 0.5-1 million annually, with 
approximately 0.6 million annual death, occurs in a ratio of 4.5:1 for men to women 
(Ferlay et al., 2010). The geographical distribution of liver cancer cases varies greatly 
worldwide, Developing countries account for 85% of the new cases of liver cancer, with 
highest rates in Asia and Africa, mainly attributed to the lack of infrastructure for 
management of this disease (Sharp et al., 2001).  In Europe and USA, liver cancer has 
recently gained major attention due to its doubling of incidence in the past 20 years, 
mainly attributed to the increasing prevalence of Nonalcoholic steatohepatitis (NASH), as 
an independent risk factor for liver cancer. Human liver cancer is morphologically and 
genetically heterogeneous, which makes its molecular pathogenesis complex. Hence 
molecular understanding of the disease remained poor. As such, the call for more in depth 
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appreciation of the disease is urgent and critical (Llovet, Villanueva, Lachenmayer, & 
Finn, 2015).  
 
1.1.2 Current therapeutic strategies for liver cancer 
Curative therapies such as surgical resection, liver transplantation and percutaneous local 
ablative treatment remained to be the top options for early HCC patients. Although long-
term control can be achieved in about 60 to 70% of these patients, recurrence rates are 
still high (Mulcahy, 2005). Treatment options are limited for advanced or terminal stage 
HCC patients, where supportive or palliative care is usually the recommended option. 
High mortality rate of HCC patients can be attributed to three main reasons: 1) Relatively 
high resistance to conventional chemotherapy and radiotherapy; 2) Heterogenity in clinic 
and genetics due to different etiologies and thus the unfeasibility of relying on one 
standard treatment across the board; 3) The asymptomatic nature of HCC, which makes it 
diagnosed mostly at the advanced system when more effective treatment options are not 
applicable anymore. In recent years, benefitting from improved knowledge on 
carcinogenesis, two predominant mechanisms of HCC molecular pathogenesis have been 
revealed: One is, cirrhosis associated with hepatic regeneration after tissue damage 
caused by hepatitis infections and toxin/environmental factors, and the other is, mutations 
occurring in one or more oncogenes or tumor suppression genes (Farazi & DePinho, 
2006). Both mechanisms have been associated with abnormalities in several critical 
signaling transduction pathways. In this aspect, the growth factor (HGF, TGF, and EGF 
etc.), MAPK, PI3K and WNT pathways are among the most important. Common 
molecular changes had been identified for HCC of different etiologies. Elucidating the 
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pathways contributing to HCC has opened up possibilities of designing drugs targeting at 
these molecular targets. Unlike conventional curative approaches to HCC, molecular 
targeted therapies aim to inhibit tumor-induced specific molecular components and its 
associated pathways. Two main classes of targeted therapies are currently available, 
namely monoclonal antibodies and small molecule inhibitors (Villanueva & Llovet, 
2011). Sorafenib, a multikinase inhibitor blocking both VEGF and MAPK/ERK pathway, 
was approved by US food and drug administration for HCC treatment in 2007 (Wilhelm 
et al., 2008). The survival times of HCC patients undertaking sorafenib significantly 
increased, from 7.9 months to 10.7 months. Since the introduction of sorafenib, there has 
been great interest in developing new targeted therapies for HCC. Till date, there are 
more than 50 reagents that are tested in almost 200 clinical trials (Villanueva & Llovet, 
2011). Drug screenings for HCC is also actively ongoing, aiming to identify new 
oncogenes as targets for therapies, and to test new compounds to block currently 
undruggable pathways or several other simultaneous pathways.  
 
1.2 Risk factors for liver cancer 
Although vaccines had been in development since 1980s, Hepatitis B and Hepatitis C 
virus (HBV and HCV) remain the main causes of liver cancer (Kumar, Singla, & 
Kacharya, 2008). Contamination of food with aflatoxins, an Aspergillus flavus-produced 
mycotoxin, is an important contributor to HCC burden in many low-income countries 
(Srivatanakul et al., 2004). In contrast, alcohol- and obesity-induced HCC are important 
risk factors for liver cancer in populations in more developed countries (Srivatanakul et 
al., 2004). Infestation with the liver flukes, Opistorchis viverrini and Clonorchis sinensis, 
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is the main cause of CCA, which is frequent in some areas in South-East Asia (Ong et al., 
2012; Sripa et al., 2007).  
 
1.2.2 Gender disparity in liver cancer 
Gender is a risk factor for liver cancer. The disparity between genders presents itself in 
two facets of the disease: incidence and progression. Males are three to five times more 
likely to develop HCC than females (Fattovich, Stroffolini, Zagni, & Donato, 2004). 
Traditionally, this gender bias had been attributed to the fact that males are more 
predisposed to known risk factors of HCC such as alcohol high consumption and 
unhealthy diet (El-Serag, 2012). However, more recent studies carried out in mouse HCC 
models have proved that even under controlled environment, males are still more than 
twice as likely to develop HCC than female (El-Serag, 2012). Carcinogens such as 
diethylnitrosamine (DEN) induced HCC also in a gender-biased manner, with 100% of 
male mice and 30% of females mice develop HCC under chronic exposure (K. V. Rao & 
Vesselinovitch, 1973). This gender disparity appears to be hormone dependent. Female 
sex hormone, estrogen, has been credited to confer protection against HCC because 
postmenopausal women have an increased HCC incidence (Mucci et al., 2001). 
Administration of estrogen to male mice inhibits the development of DEN-induced HCC 
(Nakatani, Roy, Fujimoto, Asahara, & Ito, 2001). Effects of hormones on gender disparity 
in HCC seem to be also mediated via an inflammatory mechanism. A pro-inflammatory 
cytokine, interferon gamma, has been shown to promote HCC in a male-predominant 
fashion (Rogers et al., 2007). Prolactin, dominantly expressed in females, down-regulates 
innate immune activation of a Myc liver cancer model in transgenic mice (Hefaiedh et al., 
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2013). Estrogen had been shown to directly inhibit tumor-associated macrophages 
(TAMs), which are pro-tumor in a variety of cancer types (Raggi, Mousa, Correnti, Sica, 
& Invernizzi, 2015). Furthermore, estrogen inhibits interleukin-6 production in Kupffer 
cells, liver resident macrophages, reducing liver cancer risks in female mice (Naugler et 
al., 2007). 
 
Some retrospective patient studies have shown that gender biasness in HCC exists 
beyond disease occurrence as male HCC is also more aggressive than their female 
counterpart (Dohmen, Shigematsu, Irie, & Ishibashi, 2003; Farinati et al., 2009; Hefaiedh 
et al., 2013). This is evident by the fact that females HCC patients tend to survive ~2 
times longer than males (Hefaiedh et al., 2013). Female HCC tumors are histologically 
more unifocal, more differentiated and less metastatic than male HCC (Farinati et al., 
2009). Interestingly, numerous HCC studies have demonstrated a more robust immune 
cell infiltration in males than in females. For example, infiltrating TAM density has been 
found to be higher in males than in females in a mouse HCC model (W. Yang et al., 
2012). In human HCC patients, men have considerably high numbers of intratumoral 
infiltrated CD66b+ neutrophils and CD8+ T-cells, both are indicators of poor disease 
prognosis (Y. W. Li et al., 2011). However, molecularly and mechanistically, few studies 
have been conducted to explain the molecular mechanism of gender bias in HCC 
progression.  
 
1.2.2 Nonalcoholic steatohepatitis in liver cancer 
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The most common form of chronic liver disease in developed countries is nonalcoholic 
fatty liver disease (NAFLD) (Hashimoto, Taniai, & Tokushige, 2013; Michelotti, 
Machado, & Diehl, 2013). NAFLD is rapidly becoming an epidemic. Population studies 
estimate the prevalence of NAFLD in the general population ranges from 9%-37%. (Lazo 
et al., 2013). NAFLD is a spectrum of liver pathology that ranges from elevated lipid 
accumulation in hepatocytes (steatosis) to steatosis with inflammation and fibrosis, 
commonly referred to as Nonalcoholic steatohepatitis (NASH) (Tiniakos, Vos, & Brunt, 
2010). NASH has been estimated to affect 5%-7% of the general population and as many 
as 34%-40% of patients who tested negative for serologic markers for liver disease 
(Michelotti et al., 2013). 4-22% of HCC cases in western countries are now attributed to 
NASH (Michelotti et al., 2013).  Growing evidence suggests that NASH accounts for a 
large proportion of cirrhosis even though most of the histologic hallmarks of NASH are 
not present in patients (Hashimoto et al., 2013). The histologic findings of NASH, such 
as fatty deposition, necrosis and inflammation may disappear when the disease progresses 
to cirrhosis. However, to date, how NASH transits to HCC and CCA remained elusive. A 
growing number of studies have pointed to the chronic inflammation during NASH as the 
key promoter of disease progression. Release of multiple pro-inflammatory cytokines 
including TNF-α, IL-6, leptin, and resistin, as well as decreased amounts of adiponectin 
were evident in NASH patients (Hashimoto et al., 2013). The development of NASH is 
also associated with oxidative stress and the release of reactive oxygen species (ROS) 
which likely contributes to the development of HCC. Elevated ROS production is 
observed in hepatocytes with fatty infiltration, suggesting that oxidative stress may be 
implicated in hepatic hyperplasia was demonstrated (Hashimoto et al., 2013; Sapp, 
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Gaffney, EauClaire, & Matthews, 2014).  In addition, in a choline-deficient high-fat diet 
mouse model, metabolic activation of CD8 T cells and NK cells promotes NASH to HCC 
transition via crosstalk with hepatocytes (Wolf et al., 2014). Also, targeted deletion of ikk 
exacerbated susceptibility of mouse to various type of liver injury and strongly enhance 
the development of diethylnitroamine carcinogen-induced HCC (Maeda, Kamata, Luo, 
Leffert, & Karin, 2005). However, there is basically no knowledge about the transition of 
NASH to CCA.  
 
1.3 Inflammation in liver cancer 
Rudolf Virchow first proposed the parallels between inflammation and cancer in 1863. 
Cancer initiation creates a pro-inflammatory microenvironment, followed by the 
attraction and subsequent infiltration of immune cells, the most representative 
characteristic of cancer inflammation (Ino et al., 2013). HCC is a typical inflammation 
associated cancer; with more than 90% of HCCs arising in the context of hepatic injury 
and inflammation. Chronic unresolved inflammation is associated with persistent hepatic 
injury and concurrent regeneration, leading to sequential development of fibrosis, 
cirrhosis, and eventually HCC. Irrespective of the intrinsic differences among various 
etiological factors, a common denominator at the origin of HCC is the perpetuation of a 
wound-healing response activated by parenchymal cell death and the resulting 
inflammatory cascade. Molecularly chronic inflammation in hepatocytes activates 
signaling cascades such as the JAK/STAT, NK-kB, and growth factor pathways.  Hyper 




1.3.1 Inflammatory Mediators and Signaling Pathways Associated with Liver 
Cancer  
An increasing number of studies have identified a plethora of abberant inflammatory 
mediators and signaling pathways associated in liver cancer (Berasain et al. 2009a; 
Weber et al. 2011; Nakagawa and Maeda 2012; Wai and Kuo 2012; Szabo and Lippai 
2012). For example, various inflammatory cytokines, such as IL-1β, IL-6, IL-8 and TNF-
α, participate in chronic hepatic inflammation induced by various risk factors of the 
disease (Budhu and Wang 2006; Naugler and Karin 2008). Activated Kupffer cells 
produce IL-6 which enhances local inflammatory responses, resulting in compensatory 
hepatocyte proliferation, leading to the eventual neoplastic transformation of hepatocytes 
(Naugler and Karin 2008). Increased serum IL-6 level was observed in patients with 
different stages of liver disease, including hepatitis, NASH, and HCC (Deviere et al. 
1989; Lee et al. 1998; Wieckowska et al. 2008). IL-1β, is found to promote hepatic 
stellate cell proliferation, activation, and transdifferentiation into the myofibroblastic 
phenotype (Han et al. 2004). In addition, IL-1β can promote hepatic inflammation by 
inducing the production of C-reactive protein, a sensitive marker of infection and 
inflammation  (Berasain et al. 2009a). Similar to IL-6, NF-κB has been found to be 
activated in virtually every chronic liver disease, including hepatitis, alcoholic liver 
disease, NASH, HCC and CCA (Luedde and Schwabe 2011). Inhibition of NF-κB via 
hepatocyte-specific deletion of IKK-β almost completely diminished HCC development, 
in a hepatocyte-specific lymphotoxin αβ transgenic mouse model (Haybaeck et al. 2009). 
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Hence, targeting chronic inflammation in liver disease proved to be an attractive 
therapeutic approach to prevent the disease progression.  
 
1.3.2 Role of TGFB1 in liver cancers 
One of the key inflammatory cytokines mediating almost all stages of liver disease is 
transforming growth factor beta 1 (TGFB1). During NASH, TGFB1 contributes to lipid 
accumulation by deregulation of lipid metabolism and enhancement of cell death in lipid 
accumulated hepatocytes, resulting in progression of NASH to fibrosis (L. Yang et al., 
2014). The orchestrating role of TGFB1 on the liver cancer tumor microenvironment, 
particularly the activating role on kupffer cells and hepatic stellate cells, which 
exacerbate liver fibrosis, has been well documented (Seki et al., 2007). However, 
TGFB1’s role in carcinogenesis remained controversial. In mouse models with decreased 
availability of TGFB type II receptor, HCC susceptibility is greatly increased (Kanzler et 
al., 2001). However, other studies have shown that TGFB1 also promotes HCC by 
inducing hepatocyte apoptosis and compensatory proliferation (Z. Yan et al., 2015). 
Interestingly, TGFB1 is a proposed regulator of hepatocyte to cholongiocyte 
transdifferentiation. A zebrafish transgenic model overexpressing hepatitis virus proteins 
in hepatocytes induces CCA formation, which was attributed to an elevated Tgfb1 
expression in hepatocytes (Liu et al., 2012). Furthermore, in cholangiocyte specific 
TGFB receptor II knockdown mouse model, CCA is induced, suggesting that TGFβ 
signaling restricts cholangiocyte proliferation (X. Mu et al., 2016). Despite these 
extensive studies of TGFB1 in liver disease progression, there is a lack of understanding 
on the molecular change that triggers the switch between different modes of action of 
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TGFB1. Earlier studies of TGFB1 showed that time and duration of TGFB1 expression is 
critical in the regulation of different molecular pathway activation and in turn the effect 
elicited (L. J. Ma et al., 2004; Rube et al., 2000; J. H. Sherman, Miller, Albert, & Baxter, 
1993). Interestingly, in a mouse study, hepatocyte-specific induction of Tgfb1 expression 
caused liver fibrosis but not HCC, nonetheless suggesting that Tgfb1 alone can initiate 
the liver disease progression (Ueberham et al., 2003). 
 
1.4 Tumor microenvironment in primary liver cancer 
Tumor microenvironment dynamics is a key determinant of liver disease progression. 
Transcriptomic analysis of HCC patients samples indicated survival to correlate with the 
tumor-adjacent tissues, particularly in early stage HCC patients (Hoshida et al., 2008). 
The non-neoplastic stromal composition serves as a reliable prognostic predictor in HCC 
patient survival and recurrence (Llovet, Schwartz, & Mazzaferro, 2005; M. Sherman, 
2008). Numerous studies have reported changes of the tumor microenvironment during 
HCC, including increased densities of intratumoral endothelial cells, TAMs, TANs, CD8+ 
T-cells and activated hepatic stellate cells (HSCs);  an increase in density of each cell 
type indicates poor disease prognosis (Hernandez-Gea, Toffanin, Friedman, & Llovet, 
2013; Ju et al., 2009; Y. W. Li et al., 2011; W. Yang et al., 2012). In contrast, presence of 
CD57+ natural killer cells or CD7+ B cells has been associated with small tumor size and 
better prognosis (Liang et al., 2013). The lack of a consensus role of different cell 
populations in HCC progression suggests the conflicting behavior of each of them in the 
disease. Currently, most studies in HCC-microenvironment cell interaction focus more on 
creating association and predicting prognostic outcome with a particular type of cell 
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population. They are more often conducted in well-formed primary tumors of patients. 
While such studies are crucial in term of clinical relevance, their contribution to the 
underlying mechanisms of infiltrated immune cells HCC progression, especially during 
the initiation stages, is limited. Interestingly, various risk factors of HCC have been 
demonstrated to be capable of modifying both the pretumor and tumor microenvironment 
with an inflammation-driven mechanism (Hernandez-Gea et al., 2013). For example, 
Hepatitis B and C virus activates HSCs and macrophages, thus promoting liver fibrosis 
(Seitz & Stickel, 2006). In contrast, NASH induce natural killer and CD8+ T cell 
infiltration via NFκB activation, thereby stimulating the transition from fatty liver to 
HCC (Wolf et al., 2014).  
 
1.4.1 Tumor associated neutrophils in primary liver cancers 
In the past decade, increasing evidence has indicated a dual role of neutrophils in a 
variety of tumors (Piccard, Muschel, & Opdenakker, 2012). On one hand, activated 
neutrophils are capable of killing tumor cells through oxidative bursts (Zivkovic et al., 
2007) and secretion of anti-tumor cytokines such as TNF-α and IFNs (di Carlo et al., 
2001). On the other hand, in certain situations, neutrophils have also been found to 
promote tumor progression. Tumor-associated neutrophils (TANs) have long been 
observed to correlate with tumor progression in chronic colitis-associated carcinogenesis 
or gastric adenocarcinoma (Fridlender et al., 2009; Shang et al., 2012; Zhao et al., 2012). 
These alternatively behaved neutrophils are capable of releasing growth-stimulating 
signals, matrix-degrading proteases, and angiogenesis mediators (Opdenakker & Van 
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Damme, 1992; Piccard et al., 2012), favoring tumor progression. Recently, it has been 
reported the existence of subtypes N1 (anti-tumoral) and N2 (pro-tumoral) neutrophils; 
the neutrophil plasticity appears to be regulated by transforming growth factor-beta (Tgf-
β), which are often found to be secreted by cancer cells (Fridlender et al., 2009). Naïve 
neutrophils are induced by Tgf-β to acquire a N2 phenotype, which differs from N1 
neutrophils in morphology, cytotoxicity and transcriptomic profile (Fridlender et al., 
2009; Fridlender et al., 2012).   
 
1.4.2 Tumor associated macrophage in primary liver cancers  
Macrophages can assume a plethora of different phenotypes based on the environmental 
stimuli (Cortez-Retamozo et al., 2012). The M1 phenotype is associated with active 
microbial killing, while the M2 phenotype is associated with tissue remodeling and 
angiogenesis (Shirabe et al., 2012). When infiltrated monocytes in the tumors are 
exposed to tumor-derived cytokines, such as IL4, IL10, TGFB1, they could be polarized 
into TAMs. TAMs show similar molecular and functional profiles with M2 phenotypes 
(Yeung et al., 2015). TAMs profiles are distinguished by high expression of arginase I, 
IL-1 decoy, IL-1ra, IL-6, and IL-10, and low expression of TNF and IL-12 and low 
expression of differentiation-associated macrophage antigens, such as carboxypeptidase 
M and CD51 (Cortez-Retamozo et al., 2012). Functionally, TAMs suppress the protective 
immune functions against tumor cells. For example, TAMs induce the differentiation of 
regulatory T cells thus suppress tumor-specific T-cell immunity. TAMs are also potent 
inducers of tumor angiogenesis and fibrosis, thus promoting tumor progression.   (Shirabe 




1.4.3 Crosstalk between cancer cells, neutrophil and macrophages 
The influence between neutrophils, macrophages and tumor cells are reciprocal. While 
tumor cells are capable of hyper-expressing pro-inflammatory molecules, mimicking the 
initial phase of wound formation (Coussens et al., 1999), to attract neutrophils to the 
localized tumor microenvironment (Y. Feng, Santoriello, Mione, Hurlstone, & Martin, 
2010), the recruited or infiltrated neutrophils also have pro-angiogenic effects and 
promotes epithelial to meschymal transition during tumor progression (Freisinger & 
Huttenlocher, 2014; Kuang et al., 2011). This closely linked relationship between 
immune cells and tumor cells is particularly evident in HCC, which is a typical 
inflammation-associated cancer.  
 
1.5 Using zebrafish as a model organism 
The zebrafish (Danio rerio) is a small cyprinid found in tributaries and branches of 
Ganges River in South-East Asia (Nagel, 2002). The first experimentation with zebrafish 
began as early as 1980s when Georage Streisinger established pure strains of zebrafish to 
study embryogenesis. (Streisinger, Walker, Dower, Knauber, & Singer, 1981). Now there 
is an increasing interest in using zebrafish for not only developmental biology but also 
drug screening due to several inherent advantage of the animal: small in size, low 
maintance cost, high fecundity, and a relatively short growth period to sexual maturity. 
Also, their external development and optical clarity during embryogenesis allows for 
easily observation and manipulation, facilitating in many different studies. In addition, 
there is strong genetic conservation between zebrafish and human, which makes zebrafish 
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an excellent model organism for studying complex biological processes, such as the 
generation of nervous system, liver, kidney, heart and hematopoietic system, as well as 
assessing angiogenesis, apoptosis, and toxicity response.  
 
With the emergence of new and advanced biotechnologies, the advantage of using 
zebrafish as a model organism increases. Morpholino antisense oligos have been widely 
used in zebrafish for quick and specific elucidates of gene function. The transgenic 
expression can be used not only to study the gain of function phenotypes in zebrafish but 
also to generate animal models to study specific proteins such as receptors and associated 
effectors (Parng, Seng, Semino, & McGrath, 2002). Targeted gene knockout, traditionally 
only applicable for mouse models, have also been successfully developed in zebrafish, by 
using either zinc finger nuclease, TAL effector nuclease or more recently CRISPR/CAS9  
(Irion, Krauss, & Nusslein-Volhard, 2014; Meng, Noyes, Zhu, Lawson, & Wolfe, 2008; 
Sander et al., 2011), allowing study of the loss of function of specific gene.  
 
1.5.1 Generation of zebrafish disease model  
Using animal models to understand the pathogenesis of human diseases at a cellular and 
molecular level is crucial for drug discovery and therapy development. As such, alteration 
of specific genes, generating transgenic animal for gain-of-function or loss-of-function 
studies is a necessity. Since the 1990s, hundreds of different transgenic zebrafish disease 
models have been generated, using a variety of the techniques and approaches 
aforementioned. These techniques can be broadly grouped into two major categories: 




Large scale forward genetic screens had been carried out in zebrafish using chemical 
mutagens, irradiation or insertional mutagens to introduce random mutations into the 
genome (Patton & Zon, 2001). Progeny of mutagenized adult zebrafish are screened to 
obtain an abnormal phenotype. The underlying genetic mutation is then identified 
through genetic mapping, sequencing analysis and phenotype validation. To date, about 
2000 phenotypic mutants have been generated in zebrafish through these forward genetic 
screens (K. Wang et al., 2012). Many of these zebrafish mutated genes are also 
orthologous to human genes causing congenital disease with phenotypic similarities. For 
example, in both zebrafish and human, ttn mutations lead to cardiomyopathy; tbx5 
mutation causes congenital heart defects and kcnh2 mutation results in arrhythmias (Nair 
& Pelegri, 2011).  
 
In contrast, reverse genetic approach allows direct assessment of known genes in the 
processes of disease development. Similar to forward genetic screens, this approach 
involved screening of large population of mutagenized fish for the identification of gain 
or loss of function of the particular gene of interest. To date, several key tumor 
suppressors such as tp53, pten have been identified by reverse genetics approaches (P. 
Huang, Zhu, Lin, & Zhang, 2012). Targetted gene disruption, such as zinc-finger 
endonucleases, TALEN and more recently CRISPR/Cas9, have been tailor designed to be 
applied in zebrafish (Irion et al., 2014; Meng et al., 2008; Sander et al., 2011). In contrast, 
to study the gain of function of a particularly gene, microinjection of an DNA construct 
into 1 cell stage embryos can be adopted. The efficiency of transenic technique has been 
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dramatically improved bythe development of several transposon systems such as Tol2 
and Ac/Ds, which enhance the integration of transgene into the fish genome (Clark, 
Urban, Skuster, & Ekker, 2011).  
 
From a clinical perspective, one of the most practical contributions that a zebrafish 
disease model can make is to improve diagnosis and therapy. Aside from providing 
mechanistic knowledge on disease progression, zebrafish disease models can offer an 
attractive platform for drug discovery. Zebrafish is a cost effective and highly fecund 
model organism. Rapid assays can be developed to screen for potential lead compound 
using zebrafish disease models. Lead compounds that are discovered in such screens have 
been further developed and validated in other mammalian systems.  
 
1.5.2 Using zebrafish as liver cancer models 
Chemical carcinogenesis, due to its technical simplicity, was the first approach used to 
demonstrate the spontaneous formation of benign and malignant liver tumors in 
zebrafish. DMBA and MNNG had long been demonstrated to induce formation of a 
number of neoplasms in various tissues, with hepatic tumors as one of the most 
commonly occurring lesions (Spitsbergen, Buhler, & Peterson, 2012). Interestingly, these 
zebrafish liver cancers has been shown to resemble human liver cancer not only 
histologically, but also a strong conservation of gene expression signature including 
genes involved in regulating cell cycle, apoptosis, DNA repair and metastasis (Lam et al., 
2006). The understanding of significant correlation between zebrafish and human liver 
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tumorigenesis process provided a solid foundation on which zebrafish can be used as an 
ideal model organism for the study of HCC. And recently, three transgenic zebrafish HCC 
models have been described in our laboratory, each overexpressing oncogenic mouse 
Myc, Xiphophorus Xmrk (Z. Li et al., 2012), or zebrafish KrasV12 (Nguyen et al., 2012b) 
respectively. In our HCC zebrafish model, rapid disease progression is observed, with the 
fish developing full-blown carcinoma in a few weeks upon activation of the oncogene. In 
addition, with the inducible system, the oncogene can be activated at a given and 
controlled timing, providing an excellent platform to study cancer initiation events. 
 
1.6 Aims and Objectives 
HCC is a typical inflammation associated cancer; with more than 90% of HCCs arise in 
the context of hepatic injury and inflammation (Villanueva & Llovet, 2011). Immune cell 
infiltration is a hallmark of cancer-induced inflammation (Liang et al., 2013) and this can 
be easily observed and monitored in live zebrafish larvae as several immune cell reporter 
transgenic lines are available, in particular, the popularly used neutrophil and 
macrophage reporter transgenic zebrafish, Tg(lyz:DsRed) and Tg(mpeg1:mCherry) which 
expresses DsRed or mCherry fluorescence protein in the two major innate immune cells, 
respectively (Ellett, Pase, Hayman, Andrianopoulos, & Lieschke, 2011; C. Hall, M. V. 
Flores, T. Storm, K. Crosier, & P. Crosier, 2007), The inducible nature of our zebrafish 
HCC model allows us to capture all tumor initiation events (Li et al., 2012; Nguyen et al., 
2012; Chew et al., 2015) and thus it is an ideal tool to study the effect of inflammation 
during liver cancer initiation, Thus, the first objective of this project is to delineate the 
role of inflammation on hepatocarcinogenesis, in particular, tumor initiation. Phenotypic 
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and molecular differences will be examined to pinpoint the role of tumor infiltrated 
neutrophil and macrophages during hepatocarcinogenesis.  
 
Men experience more aggressive HCC than women (Hefaiedh et al., 2013). Interestingly, 
numerous HCC studies have demonstrated a more robust immune cell infiltration in 
males than in females (Naugler et al., 2007). Men have considerably high numbers of 
neutrophils, macrophages and CD8+ T-cells, all of which are indicators of poor disease 
prognosis (Buch, Kondragunta, Branch, & Carr, 2008). Thus, the second objective of this 
study is to examine the roles of TANs and TAMs in gender disparity of liver cancer in the 
krasV12-induced zebrafish HCC model. Possible regulating mechanisms causing the 
gender difference in innate immune cell infiltration and the effect of differential 
neutrophil and macrophage infiltration will be examined.  
 
Lastly, one of the key inflammatory cytokines mediating almost all stages of liver disease 
is TGFB1 (Giannelli, Villa, & Lahn, 2014). TGFB1 have been shown to increase in 
NASH, cirrhosis and HCC patients (Giannelli et al., 2014).  However, till date, the role of 
TGFB1 in hepatocarcinogenesis remained controversial. Hence, the final goal of the 
study is to understand the effect of TGFB1 overexpression observed in liver disease 
patients. Thus, we will develop an inducible Tgfb1 overexpression zebrafish HCC model, 
which allows us to manipulate the level and the duration of Tgfb1 expression in order to 




In this project, a three-part study was carried out and three publishable manuscripts are 
resulted. Thus, the thesis is presented in the form of the three manuscripts, either 
published or currently submitted: 
1. Yan C, Huo X, Wang S, Feng Y, Gong Z (2015) Stimulation of 
hepatocarcinogenesis by neutrophils upon induction of oncogenic kras expression 
in transgenic zebrafish. J. Hepatology 63(2):420-428. 
2. Yan C, Yang Q, Gong Z (2016) Cortisol promotes gender disparity in liver 
cancer by activating tumor associated neutrophils and macrophages in zebrafish. 
Submitted. 
3. Yan C, Yan Q, Spitsbergen JM, Gong Z (2016) Overexpression of Tgfb1 causes 
both hepatocellular carcinoma and cholangiocarcinoma by switching to a 
dominant Erk pathway in zebrafish. Submitted. 
 
In addition, several related works have also been conducted in the Ph.D program and are 
not included in this thesis. Some of these works have already incorporated into published 
papers or will be incorporated into other papers submitted or in preparation, as indicated 
below: 
1. Yan Chuan, Zheng Weiling, Gong Zhiyuan. 2015. "Zebrafish fgf10b has a 
complementary function to fgf10a in liver and pancreas development." Marine 
biotechnology (New York, N.Y.) 17 (2): 162-7.  
2. Li Zhen, Luo Huaien, Li Caixia, Huo Xiaojing, Yan Chuan, Huang Xiaoqian, Al-
Haddawi Muthafar, et al. 2014. "Transcriptomic analysis of a transgenic zebrafish 
hepatocellular carcinoma model reveals a prominent role of immune responses in 
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tumour progression and regression." International journal of cancer 135 (7): 1564-
73.  
3. Li Zhen, Zheng Weiling, Wang Zhengyuan, Zeng Zhiqiang, Zhan Huiqing, Li 
Caixia, Zhou Li, Yan C, Spitsbergen JM, Gong Z 2013. "A transgenic zebrafish 
liver tumor model with inducible Myc expression reveals conserved Myc 
signatures with mammalian liver tumors." Disease models & mechanisms 6 (2): 
414-23.  
4. Li Zhen, Luo Huaien, Li Caixia, Huo Xiaojing, Yan Chuan, Huang Xiaoqian, Al-
Haddawi Muthafar, et al. 2014. "Transcriptomic analysis of a transgenic zebrafish 
hepatocellular carcinoma model reveals a prominent role of immune responses in 
tumour progression and regression." International journal of cancer 135 (7): 1564-
73.  
5. Yang Q*, Yan C*, Yin C, Gong Z(2016) Serotonin activated hepatic stellate cells 
contribute to gender disparity in hepatocellular carcinoma (Submitted) (*equal 
contribution) 
6. Zhu Q, Li M, Yan C, Lu Q, Wei S, Gao R, Yu M, Tong H, Hunziker W, Gong Z, 
Olsen B, Cao T (2016) Efficient generation of neural crest stem cells from human 
embryonic stem cells with a small molecule inhibitor/growth factor cocktail. 
(Submitted)  
7. Yan C*, Yang Q*, Gong Z(2016) Differential regulation of hepatic stellate cell in 
hepatocarcinogenesis. (In preparation) (*equal contribution) 
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8. Yan C, Yang Q, Huo X, Li H, Gong Z (2016) Chemical inhibition reveals 
different signaling pathways involved in Kras- and Myc-induced liver tumors in 
transgenic zebrafish. (In preparation) 
9. Huo X, Li H, Yan C, Li Z, Agrawal, I, Mathavan, S, Liu J, and Gong Z (2016) 
Transcriptomic profile of neutrophils in a zebrafish liver tumor initiation model 
reveals a prominent role of immune suppression and pro-angiogenesis. (In 
preparation) 
10. Huo X, Li H, Yan C, Li Z, Mathavan, S, Liu J, and Gong Z (2016) Transcriptome 
of oncogenic kras transformed liver cells reveals molecular mechanisms of 



















Stimulation of hepatocarcinogenesis by 
neutrophils upon induction of oncogenic 








In the past decade, increasing evidence has indicated a dual role of neutrophils in a 
variety of tumors (Piccard et al., 2012). On one hand, activated neutrophils are capable of 
killing tumor cells through oxidative bursts (Zivkovic et al., 2007) and secretion of anti-
tumor cytokines such as TNF-α and IFNs (di Carlo et al., 2001). On the other hand, in 
certain situations, neutrophils have also been found to promote tumor progression. 
Tumor-associated neutrophils (TANs) have long been observed to correlate to tumor 
progression in chronic colitis-associated carcinogenesis or gastric adenocarcinoma 
(Fridlender et al., 2009; Shang et al., 2012; Zhao et al., 2012). These alternatively 
behaved neutrophils are capable of releasing growth-stimulating signals, matrix-
degrading proteases, and angiogenesis mediators (Opdenakker & Van Damme, 1992; 
Piccard et al., 2012), favoring tumor progression. Recently, it has been reported the 
existence of subtypes N1 (anti-tumoral) and N2 (pro-tumoral) neutrophils; the neutrophil 
plasticity appears to be regulated by transforming growth factor-beta (Tgfb), which is 
often found to be secreted by cancer cells (Fridlender et al., 2009). Naïve neutrophils are 
induced by Tgfb to acquire a N2 phenotype, which differs from N1 neutrophils in 
morphology, cytotoxicity and transcriptomic profile (Fridlender et al., 2009; Fridlender et 
al., 2012).   
The influence between neutrophils and cancer cells are reciprocal. While tumor cells are 
capable of hyper-expressing pro-inflammatory molecules, mimicking the initial phase of 
wound formation (Coussens et al., 1999), to attract neutrophils to the localized tumor 
microenvironment (Y. Feng et al., 2010), the recruited or infiltrated neutrophils also have 
pro-angiogenic effects and promotes epithelial to meschymal transition during tumor 
25 
 
progression (Freisinger & Huttenlocher, 2014; Kuang et al., 2011). This closely linked 
relationship between immune cells and tumor cells is particularly evident in HCC, which 
is a typical inflammation-associated cancer since the primary etiological factors, hepatitis 
B and C viruses, create an unresolved, chronic inflammation of the liver (Alison, 
Nicholson, & Lin, 2011). To date, systemic therapy has not been effective in HCC 
patients (Greten et al., 2005; Thomas et al., 2008), although targeted therapy with a multi-
kinase inhibitor, sorefanib, has limited efficacy in several clinical trials (El-Serag, 
Marrero, Rudolph, & Reddy, 2008; Llovet et al., 2008). Thus, immune-based therapy 
could be a new promising approach for HCC patients. The study of the interaction 
between HCC and neutrophils should provide much needed insights into the development 
of such therapeutic approach.  
 
Recently we have generated several inducible HCC models by transgenic expression of 
an oncogene in hepatocytes in zebrafish (Chew et al., 2013; Z. Li et al., 2012; Z. Li et al., 
2013; Nguyen et al., 2012a). A major advantage of these inducible models is the temporal 
control of cancer initiation to provide an excellent opportunity to characterize tumor 
initiation events, which has been lacking in human clinical studies and other non-
inducible tumor models. Furthermore, the transparency of zebrafish larvae allows us to 
monitor early in vivo hepatocarcinogenesis and progression, thus opening up to a 
multitude of opportunities to investigate the initiation events in hepatocarcinogenesis and 
the roles of various cancer hallmark factors in the process.  In particular, we recently 
observed a prominent immune response in HCC progression and regression in one of our 
zebrafish HCC models based on RNA-seq analyses (Chew et al., 2014). In the present 
26 
 
study, the interaction of neutrophils and oncogenic hepatocytes in hepatocarcinogenesis 
was investigated. We observed a rapid recruitment of neutrophils into oncogenic liver, 
which led to accelerated tumor progression. Molecular analyses of FACS-isolated 
hepatocytes and TANs indicated changes of several important molecular pathways, 
including promotion of a pro-inflammatory microenvironment in oncogenic hepatocytes 
and decreases of anti-tumor in TANs. Thus, our data suggest a promoting role of 
neutrophils in early hepatocarcinogenesis.  
 
2.2 Materials and Methods 
2.2.1 Zebrafish husbandry 
Zebrafish were maintained in compliance with Institutional Animal Care and Use 
Committee guidelines, National University of Singapore. Four transgenic lines, 
Tg(fabp10:rtTA2s-M2; TRE2:EGFP-krasG12V) in a Tet-On system for inducible liver-
specific expression of oncogenic krasG12V (Chew et al., 2013), Tg(lyz:DsRed2) (nz50Tg) 
with DsRed-labelled neutrophils under the lysozyme C (lyz) promoter (C. Hall, M. 
Flores, T. Storm, K. Crosier, & P. Crosier, 2007), Tg(fabp10a:DsRed; ela3l:GFP) 
(gz15Tg) with DsRed-labeled liver and GFP-labeled exocrine pancreas (Korzh, Pan, 
Garcia-Lecea, Winata, Wohland, et al., 2008), Tg(mpeg1:GFP) (gl22Tg), with GFP-
labeled macrophages under the macrophage expressed gene promoter(Ellett et al., 2011) 
were used in this study and referred to as kras, lyz, fabp10 and mpeg, respectively, in the 
present report.   
 
2.2.2 Chemical treatment 
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20 µg/ml doxycycline (Sigma, D9891) were added from 3 days postfertilization (dpf) to 8 
dpf to induce krasG12V-EGFP expression. Lipopolysaccharides (LPS) (Sigma, L4391), 
FPR-A14 (Tocris, 2826),  PR-39 (Tocris, 1947) and SB431542 (Tocris, 1614) were first 
dissolved in dimethyl sulfoxide as stocks and used for larva exposure at 5 ng/ml, 2.5 µM, 
50 nM and 2.5 µM respectively from 4 to 8 dpf. The dosages were selected based on the 
highest all-survival concentrations.  
 
2.2.3 Morpholino knock-down and Tgf-β depletion 
For knockdown of Gcsfr and Irf8, previously validated morpholinos targeting each gene’s 
splice-site respectively, MO-gcsfr (5′-GAAGCACAAGCGAGACGGATGCCAT-3′) (Yi 
Feng, Renshaw, & Martin, 2012) and MO-irf8 (5’-
AATGTTTCGCTTACTTTGAAAATGG-3’) (L. Li, Jin, Xu, Shi, & Wen, 2011), were 
used. A standard control morpholino, MO-SC, (5′-
CCTCTTACCTCAGTTACAATTTATA-3′) targeting a human beta-globin intron (Gene 
Tools, Philomath, OR), was used as a negative control. Aliquots of morpholino (1 mM) 
and 1% (wt/vol) phenol red in Danieau solution were injected into embryos at the 1-cell 
stage. Doxycycline was added to all larvae from 3 dpf to 6 dpf. For Tgf-β depletion, 
antibody against zebrafish Tgf-β1 (Anaspec, 55450) was injected into 3-dpf kras+ larvae 
(1:100 dilution) at the anterior end of yolk.  
 
2.2.4 Photography and  image analysis 
At each time point of chemical treatment, morpholino knockdown and antibody depletion 
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experiments, 15-20 larvae of each group were randomly chosen for imaging. The larvae 
were anesthetized in 0.08% tricaine (Sigma, E10521) and immobilized in 3% 
methylcellulose (Sigma, M0521). Each larva was photographed separately using a 
confocal microscope (Carl Zeiss LSM510). 2D measurement of liver sizes was performed 
using ImageJ as previously described (X. Huang, Zhou, & Gong, 2012; Z. Li et al., 2013) 
and neutrophils counted manually. Neutrophils in the trunk region between the 1st to 4th 
myospetum were also counted as controls and we found no significant variations among 
all experimental conditions in this project (Supplementary Fig. 1).  Time-lapse confocal 
microscopy was conducted on 8-dpf larvae embedded in 3% low-melting-point agarose 
and the time-lapse videos were used for neutrophil tracking with multi-particle tracking 
by Imaris version 7.2.3 (Bitplane Scientific Software). 
 
2.2.5 Isolation of hepatocytes and neutrophils by FACS 
To enrich the TANs and liver cells, central part of 8-dpf larvae (after removal of the head 
and tail regions) were used for FACS using a cell sorter (BD Aria, 643245).  The liver-
enriched central parts were dissociated into single cells using a 40-µm mesh (BD falcon, 
352340) and enzymatically digested with 0.05% trypsin (Sigma, T1426), as previously 
described (Manoli & Driever, 2012). GFP+ oncogenic hepatocytes and Ds-Red+ TANs 
were isolated from doxycycline-induced kras+/lyz+ transgenic larvae, while non-
oncogenic control hepatocytes and NNs were isolated respectively from fabp10+ and 




2.2.6 RNA extraction, cDNA amplification and RT-qPCR  
Total RNA was extracted using RNeasy mini kit (Qiagen, 74104). A total of 5 ng RNA 
was used as a template to synthesize and amplify cDNA using QuantiTect Whole 
Transcriptome Kit (Qiagen, 207043). Amplified cDNA was carried out for real-time 
quantitative PCR with LightCycler 480 SYBR Green I Master (Roche, 04707516001). 
Genes of interest were amplified by 40 cycles (95°C, 20 seconds; 65°C, 15 seconds; 
72°C, 30 seconds). The sequences of primers used are presented in Table 1. Kras-EGFP 
expression under various experimental conditions was measured by RT-qPCR and there 
was no significant change of the expression observed. 
 
2.2.7 Histological and cytological analyses 
8-dpf larvae were fixed in 4% paraformaldehyde in phosphate buffered saline (Sigma, 
P6748) and paraffin-sectioned at 5 μm thickness using a microtome, followed by 
hematoxylin and eosin (H&E) staining or immunohistochemistry. For 
immunohistochemistry, the primary antibody was rabbit anti-PCNA (Santa Cruz, FL-
261), anti-caspase 3(BD biosciences, C92-065), anti-SMAD2 (Invitrogen, 700048), anti-
phosphosmad2 (Millipore, 04-953), anti-collagen 1 (Abcam, ab23730) and anti-laminin 
(Thermo, RB-082). Giemsa staining was performed on isolated neutrophils were fixed in 
100% methanol and subsequently stained with Giemsa (Sigma, GS500).  
 
2.2.8 Statistical analysis 
Statistical signiﬁcance between two groups was evaluated by two-tailed unpaired Student 
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t-test using inStat version 5.0 for Windows (GraphPad, San Diego, CA). Statistical data 
are presented as mean values±standard error of mean (SEM).. Throughout the text, 
ﬁgures, and ﬁgure legends, the following terminology is used to denote statistical 
signiﬁcance: *p<0.05, **p<0.01, ***p<0.001. 
 
2.3 Results 
2.3.1 Rapid recruitment of neutrophils into krasV12-expressing livers 
In the first study, the interaction of neutrophils and oncogenic hepatocytes in 
hepatocarcinogenesis was investigated.  To visualize inflammation response, hemizygous 
kras+ transgenic fish were crossed with lyz+ homozygous fish for production of kras+ 
and kras- offspring in the lyz+ background, DsRed expressing neutrophils were 
mornitered up to 96 hpi (hour post-induction). As shown in Fig, 2.1a and quantified in 
Figure. 2.1b-d, the total counts of neutrophils in the liver region was noticeably increased 
from as early as 8 hpi and became statistically significant from 16 hpi (Figure. 2.1b). 
These neutrophils within the vicinity of the liver, considered as TANs, were normalized 
against the liver size as neutrophil density. As shown in Figure. 2.1c, a significant 
increase in neutrophil density was observed from 8 hpi; thus, neutrophils were actively 
recruited to the site of tumor initiation within 8 hours of oncogene activation. In contrast, 
the increase of liver size became apparent only from 24 hpi (Figure. 2.1d), indicating that 
the increase of neutrophils in the liver region precedes the increase of oncogenic liver 
size. To determine whether there is a correlation between neutrophil number and liver 
size in kras+ larvae, neutrophil density and liver size were plotted for each individual 






















0.62); in contrast, such a correlation was not present in kras- siblings (Pearson’s 
coefficient, 0.20) (Figure. 2.1e).  
 
2.3.2 Acceleration of hepatocarcinogenesis by stimulation of general immune response 
and neutrophils 
To further demonstrate the role of immune cells in initiation and progression of 
hapatocarcinogenesis, we first tested a general immune activator, LPS, which has been 
demonstrated to stimulate the immune system in zebrafish larvae (Novoa, Bowman, Zon, 
& Figueras, 2009). 5 ng/ml of LPS was used to treat zebrafish larvae from 4 dpf to 8 dpf. 
kras+ larvae exposed to both LPS and doxycycline showed significant increases of both 
neutrophil count and density in the liver as compared to kras+ larvae exposed to 
doxycycline alone and all kras- groups. Interestingly, there was also a further 
enlargement of liver size with the increased neutrophils (Figure. 2.2a). To investigate if 
the accelerated liver size enlargement was indeed associated with the significant increase 
of neutrophils in the liver, FPR-A14, which is a formyl peptide receptor agonist and has 
been reported to potently activate neutrophils specifically in vitro (Schepetkin, Kirpotina, 
Khlebnikov, & Quinn, 2007), was used to challenge the kras+ larvae from 4 dpf to 8 dpf. 
Liver neutrophil count and density in FPR-A14 and doxycycline double-treated kras+ 
larvae were also significantly higher than those of their kras+ sibling treated with only 
doxycycline and of all kras- groups (Figure. 2.2b), similar to that observed in the LPS 
treatment. A further liver size increase was also observed from these double-treated kras+ 
larvae. To further demonstrate the effect of neutrophils, kras+ transgenic larvae were also 











inhibits NADPH oxidase activity in neutrophils (Hoffmeyer, Scalia, Ross, Jones, & Lefer, 
2000). As shown in Figure. 2.2c, liver neutrophil count and density as well as liver size in 
kras+ larvae exposed to PR-39 and doxycycline were all decreased as compared to kras+ 
sibling controls treated with doxycycline alone and all kras- groups. Thus, there was a 
good correlation between numbers of infiltrated neutrophils and the size of oncogenic 
liver, suggesting an in vivo promoting role of neutrophils in early hepatocarcinogenesis.  
 
2.3.3 Inhibition of neutrophil differentiation defers HCC progression 
To further validate the effect of neutrophils on tumor growth, differentiation of myeloid 
derived precursor cells into neutrophils was blocked via morpholino knockdown of the 
gcsfr gene. MO_gcsfr or control morpholino MO_SC were injected into lyz+ embryos at 
one-cell stage and injected embryos were monitored for DsRed+ neutrophils. As shown 
in Figure 2.3, by 6 dpf, there was an overall decrease of circulating neutrophils in 
MO_gscfr injected larvae, compared to those in lyz+ larvae injected with MO_SC, 
consistent with the previous report that used the same set of morpholinos (Liongue, Hall, 
O'Connell, Crosier, & Ward, 2009). kras+/lyz+ and  kras-/lyz+ zebrafish embryos were 
then injected with MO_gscfr and analyzed at 6 dpf after doxycycline induction from 3 
dpf (Figure. 2.4a and b). Similar to the observations with the PR-39 inhibitor, a 
significant decreases of neutrophil counts and density in the liver (Figure. 3.4d and e) as 
well as liver size (Figure. 2.4f), further confirming promoting role of neutrophils in the 
































To evaluate the role of macrophages in our model, depletion of macrophages was carried 
out by morpholino knockdown of the irf8 gene (L. Li et al., 2011). As shown in Fig. 
S3B,C, when mpeg+ embryos were injected with MO_irf8, GFP expressing macrophages 
were greatly eliminated; meanwhile, there was a compensating increase of neutrophils 
(Figure. 2.3), consistent with the previous report that knockdown of irf8 causes the  
 
common progenitor cells to differentiate to neutrophils (L. Li et al., 2011). When 
MO_irf8 was injected into kras+/lyz+ embryos, we observed a significant increase of 
neutrophil counts and density in the liver (Figure. 2.4c-e) with a corresponding increase 
of liver size (Figure. 2.4f). While the depletion of macrophage experiment may not be 
conclusive for the role of macrophage in early hepatocarcinogenesis, it did demonstrate 
that neutrophils alone retain the prompting activity.  
 
2.3.4 Stagnant migratory pattern of tumor infiltrate neutrophils 
Neutrophil migratory pattern was also examined using confocal time-lapse video and 
there was an obvious difference in neutrophil movement between kras+ and kras- larvae 
in the presence of doxycycline. In 1-hour time-lapse video of 8-dpf kras+ larvae, 
neutrophils had active migratory movement surrounding the liver. However, within the 
liver, infiltrated neutrophils were rather stationary with only minimal movement. In kras- 
siblings, in contrast, neutrophils were uniformly active both within and outside the liver. 
The difference was further illustrated by tracking neutrophil movement from these videos 
using the Imaris software (Figure. 2.5a and b). Thus, the tumor microenvironment leads 
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to an inactive migratory behavior of infiltrated neutrophils.   
 
2.3.5 Increase of segmented nuclei of TANs 
It has been reported that TANs in rodent models have distinct nuclear morphology with a 
high percentage of segmented nuclei (Fridlender et al., 2009). To examine whether our 
isolated TANs also displayed similar nuclear morphology, Giemsa staining on FACS-
isolated neutrophils was performed. The neutrophil nuclei were characterized into three 
broad categories according to Fridlender et al. (Fridlender et al., 2009): i) round nuclei 
denoting a naive status; ii) bi-lobed structure representing fully differentiated and mature 
neutrophils; iii) hyper-segmented nuclei frequently associated with tumors (Figure 2.5c). 
In both kras- and kras+ transgenic zebrafish, round nuclei represented 20-30% of the 
isolated neutrophils. In kras- larvae, the remaining neutrophils had bi-lobed nuclei (75%) 
and only a very small percentage (3%) had hyper-segmented nuclei (Figure 2.5d). 
However, in kras+ larvae, hyper-segmented nuclei neutrophils made up of 43% of total 
neutrophil population (Figure 2.5d), suggesting that our isolated neutrophils from the 
doxycycline-induced kras+ larvae were indeed enriched with TANs.  
 
2.3.6 Promotion of proliferation and suppression of apoptosis in krasG12V-expressing 
hepatocytes by infiltrated neutrophils 
To identify the causative factors for liver size change when neutrophil activity was 
moderated, hepatocyte proliferation and apoptosis were examined. As shown in Fig. 2.6, 
































































doxycycline-induced kras+ larvae, suggesting highly aberrant cell division and death in 
oncogenic livers. While co-exposure to FPR-A14/doxycycline did not induced a further 
increase of proliferating hepatocytes, it did lead to a significant reduction of apoptotic 
hepatocytes. In contrast, co-treatment of kras+ larvae with PR-39/doxycycline reduced 
the number of proliferating hepatocytes and increased the number of apoptotic 
hepatocytes. Thus, these observations are consistent with the change of liver size 
observed (Figure. 2.6)  
 
2.3.7 Moderated histological phenotype of oncogenic hepatocytes by inhibition of 
neutrophil activity 
Histologically, as shown in Figure 2.7a, all H&E staining of 8-dpf kras+ larvae exposed 
to doxycycline showed histological features of early carcinoma, e.g. dense cell plate, 
large nucleus-to-cytoplasm ratio and pseudo glandular patterns. All kras+ larvae exposed 
to FPR-A14 and doxycycline showed similar early carcinoma histology, but with 
significantly less proportion of normal tissue, suggesting that the additional exposure to 
FPR-A14 had further stimulated HCC progression. In contrast, most kras+ larvae 
exposed to PR-39 and doxycycline did not display the early carcinoma phenotype and 
instead resembles closely to the liver phenotype of control kras- larvae, implying 
exposure to PR-39 deters progression into HCC.   Figure. 2.7b summarizes the 
quantitative distribution of histological phenotypes in each treatment group, further 
indicating that inhibition of neutrophils led to moderated tumor phenotype while 
























2.3.8 Pro-inflammatory microenvironment of oncogenic liver and reduction of anti-tumor 
activities of TANs 
It has been well established that cancer cells are capable of creating a pro-inflammatory 
microenvironment (Grivennikov, Greten, & Karin, 2010; Kuraishy, Karin, & 
Grivennikov, 2011). To investigate molecular interaction of oncogenic hepatocytes and 
neutrophils in our model, GFP-krasG12V-expressing hepatocytes were isolated from 
doxycycline-treated kras+ larvae by FACS and meanwhile enriched TANs were isolated 
based on DsRed expression (Figure 2.8a). RT-qPCR analysis of kras+ hepatocytes  
(Figure. 2.8b) showed a significant up-regulation of tgfb1a, a primary regulator in early 
development of liver fibrosis and cancer-related inflammation (Matsuzaki et al., 2007; 
Ling Yang et al., 2013). In contrast, key anti-tumor genes such as tnfa and ifng showed 
significant down-regulation. Meanwhile, compared to NNs, TANs showed a general pro-
tumor gene expression pattern. For instance, il1b, which promotes early cancer 
angiogenesis (Carmi et al., 2013), was significantly up-regulated while anti-tumor 
cytokines, il4, il6, il8, il10, il12 and tnfa, all showed significant down-regulation (Figure 
2.8c). Tgfb1 is known to polarize neutrophils to a pro-tumor phenotype (Fridlender et al., 
2009). To investigate if oncogenic hepatocyte-secreted Tgfb1 mediated crosstalk between 
the two cell types, SB431542, a specific inhibitor of Tgfb type I receptor (Halder, 
Beauchamp, & Datta, 2005; Z. Sun et al., 2006), was used to block Tgfb signaling in 
TANs. Compared to unblocked TANs, significant up-regulation of all but one examined 

























































TANs. Thus, blockage of Tgfb1 signaling partially rescued the expression of these anti-
tumor genes (Figure. 2.8d).  
 
Since Tgfb1 has been reported to be a chemoattractant for neutrophils (Reibman et al., 
1991), we further depleted Tgfb1 by injection of zebrafish Tgfb1 antibody into 3-dpf 
kras+/lyz+ zebrafish as well as by SB431542 inhibition. We noticed reduced neutrophils 
in the liver by 8 dpf by both approaches (Figure 2.9a and c) as confirmed by the 
decreases neutrophil counts and density in the liver, which was also accompanied with a 
decrease in liver size (Figure 2.9b and d). The successful depletion of Tgfb1was 
supported by a significant reduction of phosphorylated Smad2, a downstream marker of 
the Tgfb1 pathway in both neutrophils and hepatocytes (Figure. 2.9e and f). Collectively, 
these experiments demonstrate the role of Tgfb1, to cause the attract neutrophils to the 
liver upon oncogenic kras induction in hepatocytes. 
 
2.4 Discussion  
2.4.1 Rapid response of neutrophils to a pro-inflammatory microenvironment created by 
oncogenic krasV12-expressing hepatocytes 
The chronic, unresolved inflammation is well recognized as one of the hallmarks and a 
contributing factor of early HCC. Persistent inflammation of the liver drives hepatocyte 
apoptosis and compensatory proliferation, while prolonged abnormal regeneration 
potentially promotes hepatic damage, fibrosis, cirrhosis and eventually HCC (Weber, 
Boege, Reisinger, & Heikenwalder, 2011). TGFB plays a crucial role in the progression 
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of the liver disease as the initial damage of liver up-regulates TGFB to lead to a wound-
healing response (Margadant & Sonnenberg, 2010). In our krasV12 transgenic model, 
krasG12V-expressing hepatocytes displayed an up-regulation of tgfb1a and down-
regulation of anti-tumor genes, tnfα and ifng. The gene expression pattern indicated that 
the oncogenic kras+ hepatocytes favored a pro-inflammatory environment, consistent 
with a previous report of liver tumors arising from inflammation due to chronic injury 
(Khatib et al., 2005). Moreover, decreased expression of tnfα and ifng aids in the creation 
of a pro-tumor microenvironment, which is in line with clinical HCC data (Kuppen et al., 
1997; Lee et al., 2013). Thus, oncogenic krasV12 expression have created a pro-
inflammatory microenvironment in the HCC initiation stage of HCC and down-regulation 
of important anti-tumor genes further facilitates the disease progression.  Moreover, TAN 
showed significant down-regulation of a variety of anti-tumor cytokines, including il4, 
il6, il8, il10, il12 and tnfg, and up-regulation of pro-tumor il1b. These observations 
indicate a crosstalk between the oncogenic hepatocytes and neutrophils. Oncogenic 
hepatocytes secrete high level of Tgfb1 which recruit neutrophils as it has been 
demonstrated to be a potent chemoattractant of neutrophils (Reibman et al., 1991). We 
further validated that depletion of Tgfb1 resulted in a significant reduction of neutrophil 
density in the oncogenic livers, which causes a decrease of oncogenic liver size compared 
to oncogenic liver without Tgfb depletion. However, the liver size remains significantly 
larger than the size of liver of kras- controls, which may indicate multiple roles of Tgf-β, 
including a suppressor in early tumor progression (Tang et al., 2003). Once the 
neutrophils were recruited, a high level of Tgfb1 in oncogenic hepatocytes further causes 
TANs to reduce expression of anti-tumor genes and increase in il1b. Increased in 
50 
 
expression of il1b in TAN hinted the possible angiogenesis promoting role of TAN in 
HCC. Blockade of the Tgfb1 signaling pathway by SB431542 showed a partial rescue of 
the pro-tumor gene expression profile in TAN, further validating the molecular crosstalk 
between the two cell types. 
 
2.4.2 Acceleration of HCC progression by TANs 
Our data indicated a good correlation between the number/density of liver-infiltrated 
neutrophils and the size of oncogenic liver; thus, it is likely that neutrophils play a 
stimulating role in liver tumor initiation and progression. This phenomenon has been 
further confirmed by pharmacological experiments. Both the general immune stimulator 
LPS and neutrophil-specific activator FRP-A14 caused further increase of liver-infiltrated 
neutrophils and also further increase of the liver size. Conversely, neutrophil inhibitor, 
PR-39, caused a reduction of liver-infiltrated neutrophils and also slowed down the 
growth of oncogenic liver. In addition, our unpublished data using Irf8 morpholino to 
deplete macrophages and thus increase neutrophil density showed neutrophil alone also 
have a significant effect in accelerating HCC progression.  
 
Histologically, the severity of oncogenic livers also correlated to the activity of 
neutrophils. There was a rapid oncogenic transformation of hepatocytes upon krasG12V 
induction and histological HCC phenotype could be observed within four days of 
doxycycline induction. Neutrophils likely play an important role in this process as 
inhibition of neutrophils by PR-39 resulted in a liver histology close to a normal liver. 
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The possible explanation of the neutrophil-accelerated tumorigenesis lies in the ability of 
neutrophils to induce proliferation and inhibit apoptosis in oncogenic hepatocytes. 
Enhancement of the neutrophil activity using an activator showed a further increase in 
hepatocyte proliferation and inhibition of apoptosis. In contrast, opposite effects were 
observed by inhibition of neutrophil activity with PR-39. 
 
2.4.3 Characteristic and behavior changes of neutrophils in tumor microenvironment 
It has been well documented that neutrophils are a heterogeneous population and the 
characteristic and behavior of TANs and non-infiltrated neutrophils are markedly 
different (Fridlender et al., 2009). In our study, we also noticed several major differences 
between TANs from oncogenic kras+ larvae and NNs from kras- control larvae. First, 
migratory pattern of TANs appears to be relatively active when the cells were meandering 
along the tumor perimeter, and become relative motionless in the tumor, while the 
migration of NNs in kras- larvae are uniformly active regardless of their locations. 
Second, Giemsa staining of TANs showed a high percentage of hyper-segmented nuclei, 
which is consistent with the report  that pro-tumor N2 neutrophils in mouse models have 
hyper-segmented nuclear structure while anti-tumor N1 neutrophils have largely round 
nucleus morphology (Fridlender et al., 2009). Third, by RT-qPCR analyses, TANs 
showed down-regulation of anti-tumor genes (e.g, il4 il,6, il8, il10, il12 and tnfa) and up-
regulation of pro-tumor genes such as il1b, which also promotes early cancer 
angiogenesis (Carmi et al., 2013), indicating a potential role of TANs in pro-angiogenesis 
in HCC initiation. A complete search for more critical genes expressed in TANs for 
promoting early hepatocarcinogenesis could be carried out in future by RNA-Seq 
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analyses in our present model. 
 
In sum, our study suggests that oncogenic krasG12V expression in hepatocytes favors a 
pro-inflammatory microenvironment by increased Tgf-β1a expression, which attracts a 
rapid recruitment of neutrophils to oncogenic livers. These liver-infiltrated neutrophils 
have stimulating roles in early hepatocarcinogenesis and they lost anti-tumor activity. Our 
data are consistent with the view that the presence of neutrophils in the tumor 
microenvironment is an important marker in the aggressiveness of the liver cancer 
progression (H.-L. Rao et al., 2012; J. Wang et al., 2014). A high neutrophil density in the 
tumor would be an indicator of high hyperplasia and low apoptosis. Thus, Neutrophils are 
not bystanders in hepatocarcinogenesis and instead they are actively promoting its 










Chapter 3:  
Cortisol promotes gender disparity in 
hepatocellular carcinoma by activating 
tumor associated neutrophils and 








Hepatocellular carcinoma (HCC) is a gender-biased disease as men are 3-5 times more 
likely to develop HCC than women.(Fattovich et al., 2004; Yeh, Chang, Wei, & Wang, 
2013). Men generally have more aggressive HCC than women,(Dohmen et al., 2003; 
Farinati et al., 2009; Hefaiedh et al., 2013) as female HCC patients tend to survive ~2 
times longer than male HCC patients (Buch et al., 2008). Histologically, female HCC 
tumors are more unifocal with more differentiated and less metastatic cancer cells than 
male HCC tumors.(Farinati et al., 2009) Traditionally, this gender bias had been 
attributed to the fact that men are more predisposed to known risk factors of HCC such as 
high alcohol consumption and unhealthy diet.(El-Serag, 2012) However, laboratory 
mouse experiments under controlled conditions similarly indicated that males were more 
likely to develop HCC than females, with 100% of males and 30% of female developing 
HCC under chronic carcinogen exposure.(K. V. Rao & Vesselinovitch, 1973) The gender 
disparity appears to be hormone dependent. Female hormone, estrogen, has been credited 
with conferring protection against HCC since postmenopausal women have an increased 
HCC incidence.(Mucci et al., 2001) Similarly, prolactin, dominantly expressed in 
females, down-regulates innate immune activation in a Myc-induced liver cancer model 
in transgenic mice.(Hefaiedh et al., 2013) Notably, the gender disparity in HCC seems to 
be also mediated by an immune cell-mediated mechanism. Estrogen inhibits interleukin-6 
production in Kupffer cells (resident macrophages) in the liver and reduces liver cancer 
risks in female mice.(Naugler et al., 2007) Interestingly, numerous HCC studies have 
demonstrated a more robust immune cell infiltration in males than in females. For 
example, infiltrating TAM density has been found to be higher in males than in females 
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in a mouse HCC model (W. Yang et al., 2012). In human HCC patients, men have 
considerably high numbers of intratumoral infiltrated CD66b+ neutrophils and CD8+ T-
cells, both of which are indicators of poor disease prognosis (Y. W. Li et al., 2011). 
 
However, despite these studies on experimental animals, several previous clinical trials 
targeting sex hormone pathways conducted showed no significant improvement in HCC 
patient survival.(Di Maio et al., 2006) Clearly, the mechanisms regarding male bias in 
HCC remain to be elucidated for clinical benefits. Recently we have generated several 
inducible HCC models by transgenic expression of an oncogene in hepatocytes in 
zebrafish.(Chew et al., 2013; Z. Li et al., 2012; Z. Li et al., 2013; Nguyen et al., 2012a; L. 
Sun, Nguyen, Spitsbergen, & Gong, 2015) With the inducible system, the oncogene can 
be activated at a given and controlled timing in both genders, providing an excellent 
platform to study gender disparity in HCC initiation and progression in a controlled 
environment. In this study, we found in our krasV12-expressing tumor model that male 
transgenic zebrafish showed accelerated carcinogenesis as compared to female 
counterparts. Interestingly, cortisol was highly produced in males and it contributed to 
enhanced infiltration of tumor associated neutrophils (TANs) and TAMs in male 
oncogenic liver. Consequently, the pro-tumor TANs and TAMs accelerated HCC in a 
male-biased manner. The increased cortisol level and TGFB1 expression in male HCC 
were also confirmed from human patient samples; thus cortisol is likely also involved in 
gender disparity of human HCC. 
 
3.2 Materials and Methods 
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3.2.1 Zebrafish husbandry 
Zebrafish were maintained in compliance with Institutional Animal Care and Use 
Committee guidelines, National University of Singapore. Four transgenic lines, 
Tg(fabp10:rtTA2s-M2; TRE2:EGFP-krasG12V) (gz32Tg) in a Tet-On system for inducible 
hepatocyte-specific expression of oncogenic krasG12V (Chew et al., 2013), 
Tg(fabp10a:DsRed; ela3l:GFP) (gz15Tg) with DsRed-labeled liver and GFP-labeled 
exocrine pancreas,(Korzh, Pan, Garcia-Lecea, Winata, Wohland, et al., 2008) 
Tg(lyz:DsRed2) (nz50Tg) with DsRed-labelled neutrophils under the lysozyme C (lyz) 
promoter(Chris Hall et al., 2007), Tg(mpeg1:GFP) (gl22Tg), with mCherry-labeled 
macrophages under the macrophage expressed gene promoter(Ellett et al., 2011) were 
used in this study and referred to as kras, fabp, lyz, and mpeg, respectively, in the present 
report.   
 
3.2.2 Chemical treatment 
All chemical/reagent treatments were conducted in larvae from 3 days postfertilization 
(dpf) to 6 dpf and in 3-month old adult fish for 7 days unless otherwise specified. The 
chemicals/reagents used included doxycycline (dox) (Sigma), mifepristone (Sigma) and 
hydrocortisone (Sigma). 30 µg/L dox was used for induction of krasv12 expression as 
previously reported.(Yan, Huo, Wang, Feng, & Gong, 2015) Mifepristone and 
hydrocortisone were used for adult exposure at 2 µM and 10 mg/L respectively. The 





3.2.3 Morpholino knock-down  
For knockdown of Gcsfr and Pu.1, previously validated gene-specific morpholinos were 
used, including MO-gcsfr (5′-GAAGCACAAGCGAGACGGATGCCAT-3′)(Yi Feng et 
al., 2012) and MO-pu.1 (5’- GATATACTGATACTCCATTGGTGGT-3’)(Bukrinsky, 
Griffin, Zhao, Lin, & Banerjee, 2009). A standard control morpholino, MO-control (5′-
CCTCTTACCTCAGTTACAATTTATA-3′) targeting a human beta-globin intron 
(GeneTools, Philomath, OR, USA), was used as a negative control. Aliquots of 
morpholino (1 mM) and 1% (wt/vol) phenol red in Danieau solution were injected into 
embryos at the 1-cell stage. Dox was added to all larvae from 3 dpf to 6 dpf. 
 
3.2.4 Photography and image analysis 
At each time point of chemical treatment and morpholino knockdown experiments, 10 
adult fish or 15-20 larvae of each group were randomly collected for imaging analyses. 
Adult zebrafish were anesthetized in 0.08% tricaine (Sigma) and larvae immobilized in 
3% methylcellulose (Sigma) before imaging. Adult zebrafish were photographed with 
Olympus microscope and larvae were photographed using a confocal microscope (Carl 
Zeiss LSM510). Measurement of 2D liver sizes was performed using ImageJ as 
previously described(X. Huang et al., 2012; Z. Li et al., 2013), and neutrophils and 
macrophages counted manually.  
 
3.2.5 Isolation of hepatocytes, neutrophils and macrophages by FACS  
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5-8 Adult zebrafish livers were sampled and pooled. In larvae, to enrich the TANs, TAMs 
and hepatocytes, central part of 6-dpf larvae (after removal of the head and tail regions) 
were used for FACS using a cell sorter (BD Aria).  Adult livers or enriched larval livers 
were dissociated into single cells using a 40-µm mesh (BD biosciences, San Jose, CA, 
USA) and enzymatically digested with 0.05% trypsin (Sigma), as previously described 
(Manoli & Driever, 2012). GFP+ oncogenic hepatocytes (OHs)，Ds-Red+ TANs and 
mCherry+ TAMs were isolated from dox-induced kras+, kras+/lyz+, kras+/mpeg+ 
transgenic larvae, while non-oncogenic control hepatocytes, naïve neutrophils (NNs) and 
naïve macrophages (NMs) were isolated respectively from dox-treated fabp10+, lyz+ and 
mpeg+ control larvae based on Ds-Red or mCherry expression.  
 
3.2.6 RNA extraction, cDNA amplification and RT-qPCR (reverse transcription-
quantitative PCR) 
Total RNA was extracted using RNeasy mini kit (Qiagen, Hilden, Germany). A total of 5 
ng RNA was used as a template to synthesize and amplify cDNA using QuantiTect Whole 
Transcriptome Kit (Qiagen). Amplified cDNA was used for real-time quantitative PCR 
with LightCycler 480 SYBR Green I Master (Roche Diagnostics, Indianapolis, IN, USA). 
Interested genes were amplified for 40 cycles (95°C, 20 seconds; 65°C, 15 seconds; 
72°C, 30 seconds). The sequences of primers used are presented in Supporting Table 1.  
 
3.2.7 Histological and cytological analyses 
10 Adult livers or 20 6-dpf larvae were fixed in 4% paraformaldehyde in phosphate 
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buffered saline (Sigma) and paraffin-sectioned at 5 µm thickness using a microtome, 
followed by hematoxylin and eosin (H&E) staining or immunohistochemistry. For 
immunofluorescence staining, the primary antibodies used included rabbit anti-PCNA 
(Santa Cruz technology, Santa Cruz, CA, USA), anti-caspase 3 (BD biosciences, San 
Jose, CA, USA), anti-cortisol (Sigma, USA), anti-HSD11b (Novus bio, USA) or anti-
Tgfb1 (Millipore, Billerica, MA, USA). 
 
3.2.8 Statistical analysis 
Statistical signiﬁcance between two groups was evaluated by two-tailed unpaired Student 
t-test using inStat version 5.0 for Windows. Statistical data are presented as mean 
values±standard error of mean (SEM). 
 
3.2.9 Human patient samples  
Paraffin-embedded human liver disease progression tissue microarray slides were 
purchased from Biomax Inc (LV8011a). Patients were classified into 3 groups: Normal 
(N=5), pre-HCC (N=23) and HCC (N=30). These patient samples were subjected to H&E 
staining and IHC staining for HSB11B, cortisol and TGFB1 respectively.  
 
3.3 Results  
3.3.1 More aggressive HCC promotion in male krasV12-expressing livers  
In human, male patients develop more aggressive HCC, with larger tumor and lower 
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survival rate, than female patients (Dohmen et al., 2003; Farinati et al., 2009; Hefaiedh et 
al., 2013). To examine if krasV12-induced zebrafish HCC is similar in a male-biased 
manner, 3-month-old male and female kras+ zebrafish were exposed to dox for 7 days 
and their state of tumor progression was examined. Morphologically, male krasV12-
expressing livers cover a larger area in the abdomen than female krasV12-expressing livers 
(Figure 3.1a), accompanied with more severe histopathological features (Figure 3.1b). In 
male krasV12-expressing livers, oncogenic hepatocytes (OHs) were densely arranged with 
prominent nucleolus; the typical two-cell plate of hepatocytes observed in wildtype (WT) 
siblings were completely abrogated, denoting an early carcinoma status. In comparison, 
although female krasV12-expressing livers had more prominent nucleoli and vacuolated 
cytoplasm, the integrity of the two-cell plate was largely maintained, with the majority 
having only hyperplasic histology (Figure 3.1b). As summarized in Figure 4.1d, 80% of 
the krasV12-expressing males had reached either adenoma or carcinoma stage while only 
30% of krasV12-expressing females showed adenoma phenotypes. To further investigate 
the mechanism of the gender disparity in liver morphology and histology, cell 
proliferation analysis was performed. As expected, krasV12-expressing hepatocytes had a 
higher rate of cell proliferation than their WT siblings (Figure 3.1c and e). When 
comparing between genders, male krasV12-expressing hepatocytes had significantly 





















accounting for the difference in liver size between krasV12-expressing genders.  
 
To further elucidate the molecular mechanism of the gender disparity, expression of 
selected biomarker genes in FACS isolated krasV12-expressing OHs was compared with 
control hepatocytes from WT siblings of the same gender. Liver fibrosis related genes 
(col1a1b and lamα5), angiogenesis genes (vegfab and vegfc), epithelial-to-mesenchymal 
transition genes (snail and slug) and neutrophil and macrophage chemoattractant genes 
(il8 and csf1a) all showed higher levels of increased expression in male OHs than female 
OHs as compared to their WT siblings of the same gender (Figure 3.2). In contrast, 
known anti-tumor cytokines, il12 and tnfa were more up-regulated in female OHs than 
male OHs. Expression of egfp-krasV12 was consistent and similar between male and 
female kras+ zebrafish, suggesting the difference in expression of these biomarker genes 
was due to a gender mediated mechanism rather than a difference in induced krasV12 
expression (Figure 3.2).  
  
3.3.2 Higher TAN and TAM infiltration in male krasV12-expressing livers  
Gender disparity in HCC has been linked to differential immune cell responses between 
genders (Naugler et al., 2007). To detect a similar gender-discrepant response of 
neutrophils and macrophages in the kras+ zebrafish, kras+lyz+ and kras+mpeg+ double 
transgenic zebrafish were generated to observe for liver infiltration of neutrophils and 
macrophages. As shown in Figure 3.3a and b, krasV12-expressing livers attracted 























infiltration of neutrophils (defined as TANs) and macrophages (defined as TAMs) in male 
krasV12-expressing liver than female krasV12-expressing liver (Figure 3.3c and d).  
 
Since TAN and TAM infiltration showed a male biased manner, a more pro-tumor 
behavior of these innate immune cells would explain the advanced disease status in male 
krasV12-expressing zebrafish. Gene expression profiles of FACS-isolated TANs and 
TAMs from livers of male and female adult krasV12-expressing zebrafish were compared 
with NNs and NMs of their own gender. Both male TANs and TAMs showed higher 
increased expression of pro-tumor (il10) and chemoattractant genes (il8 and csf1a) than 
female TANs/TAMs (Figure 3.4). In contrast, phagocytic enzyme genes (mpx, lyz and 
mpeg) and an anti-tumor gene (il12) were down-regulated in male TANs/TAMs as 
compared to female TANs/TAMs. Thus, both TANs and TAMs in male krasV12-
expressing livers showed higher pro-tumor activity than those in female counterparts and 
they may contribute to the more severe HCC phenotype in males.  
 
3.3.3 Acceleration of hepatocarcinogenesis by TANs and TAMs 
To elucidate the roles of TANs and TAMs during krasV12-induced carcinogenesis, splice-
blocking morpholinos, MO-gcsfr and MO-pu.1, were used to inhibit differentiation of 
neutrophils or macrophages in krasV12-expressing larvae, respectively. The effects of these 
morpholinos were validated by injection into lyz+ embryos or mpeg+ embryos (Figure 
3.5). As we previously reported (C. Yan et al., 2015), MO-gcsfr greatly decreased both 











































































larvae as compared to kras+ larvae injected with MO-control (Figure 3.6a-c). When MO-
pu.1 was used to inhibit macrophage differentiation in kras+ larvae, both macrophage 
density in the liver and liver size were significantly decreased as compared to kras+ 
controls injected with MO-control (Figure 3.6b and c). Hence, both  
 
TANs and TAMs appear to play an accelerating role during liver carcinogenesis. Lastly, 
co-injection of both MO-gcsfr and MO-pu.1 to deplete both TANs and TAMs in kras+ 
larvae, a more profound decrease in liver size was observed (Figure 3.6b and c). To 
investigate if the changes of liver size were due to cell cycle aberration, cell proliferation 
and apoptosis analyses were performed. As summarized in Figure 4.6d, decreased 
infiltration of TANs and TAMs into krasV12-expressing livers was corresponded to a 
decreased cell proliferation and increased apoptosis (Figure 3.6d). Molecularly, TANs 
and TAMs showed a consistent changes of gene expression profiles: chemoattractant 
genes (il8 and csf1a), pro-tumor and inflammatory genes (nfκb2, cxcl1 and il1b) were 
significantly up-regulated while expression of anti-tumor and phagocytic genes (il12, 
tnfa, mpx, lyz and mpeg), were less increased or down-regulated (Figure 3.6e). 
 
3.3.4 Differential cortisol activities in genders induced differential activities of TANs and 
TAMs  
To further understand the roles of TANs and TAMs in gender disparity in krasV12-
expressing livers, possible molecular mechanisms were interrogated. Tgfb1 is a well-
known inducer of pro-tumor phenotype in neutrophils and macrophages (Fridlender et al., 
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2009) and has been demonstrated to be required for recruitment of TANs into krasV12–
expressing zebrafish livers in our previous study (C. Yan et al., 2015). Interestingly, 
cortisol, a well-known adrenal gland hormone involved in stress response (Jeejeebhoy, 
Bruce-Robertson, Ho, & Sodtke, 1972; Lippi, Franchini, Salvagno, Montagnana, & 
Guidi, 2008), has been reported to up-regulate the expression of tgfb1 in a variety of cell 
types such as T-cell, fibroblast and osteoblasts (Peltier et al., 2003; Reyes-Moreno et al., 
1995). Hence, to investigate whether cortisol was involved in gender disparity in liver 
tumors, immunostaining with cortisol antibody confirmed a significantly higher cortisol 
level in the liver section of krasV12–expressing males than females (Figure 3.7a). RT-
qPCR analyses on three key genes in cortisol synthesis, cyp11a1, cyp17a1 and hsd11b1 
showed higher up-regulation of the three genes in OHs in males than in females as 
compared to control hepatocytes from WT siblings (Figure 3.7b). This was also 
confirmed by immunostaining with Hsd11b antibody (Figure 3.7c). To investigate if the 
role of cortisol was through Tgfb1, male kras+ fish were co-treated with dox and 
mifepristone (a glucocorticoid receptor inhibitor) and female kras+ fish were co-treated 
with dox and hydrocortisone (a cortisol analog). Both tgfb gene and protein expression 
were consistently inhibited by mifepristone in kras+ males; in contrast, additional 
cortisol in kras+ females caused increase of tgfb1 mRNA and protein (Figure 3.7d and e).  
 
To demonstrate if cortisol could cause an increase of neutrophils and macrophages, 4-dpf 
larvae were treated with 5 µM of cortisol for 4 days, indeed there were increases of both 
total neutrophils and macrophages after cortisol treatment accompanied with increases of 



































































infiltration of TANs and TAMs in krasV12-expressing livers, kras+mpeg+ and kras+lyz+ 
males were co-treated with dox and mifepristone while kras+mpeg+ and kras+lyz+ 
females were co-treated with dox and hydrocortisone. As shown in Figure 3.9a-d, 
inhibition of cortisol signaling in kras+mpeg+ and kras+lyz+ males decreased TAM and 
TAN infiltration significantly while increase of cortisol in kras+mpeg+ and kras+lyz+ 
females increased TAM and TAN infiltration significantly. Molecularly, TANs and TAMs 
in both co-treated krasV12-expressing males and females showed reversals of gene 
expression in phagocytic (lyz, mpx and mpeg), pro-tumor (il10), anti-tumor (il12) and 
chemoattractant (csf1a and il8) genes (Figure 3.10).  These experiments established that 
cortisol is involved in liver tumor infiltration of TANs and TAMs through the Tgfβ signal, 
which in turn stimulate liver carcinogenesis.  
 
3.3.5 High cortisol in adult male krasV12-expressing liver accelerates carcinogenesis 
To further demonstrate if cortisol induced TAN and TAM infiltration could enhance 
carcinogenesis, liver tumor progression was investigated in male and female kras+ 
zebrafish treated with mifepristone or hydrocortisone together with dox. 
Morphologically, dox and mifepristone double-treated kras+ males showed slightly 
smaller livers than the kras+ males treated with dox only. In contrast, kras+ female fish 
treated with hydrocortisone showed significantly enlarged livers even compared with the 
two kras+ male groups, suggesting accelerated carcinogenesis (Figure 3.11a).  
 


















and were more hyper-vacuolated than kras+ males treated with dox alone, with fewer 
fish reaching adenoma or carcinoma (Figure 3.11b and c). In contrast, all kras+ female 
fish treated with hydrocortisone and dox showed either adenoma or carcinoma (Figure 
3.11b and c). From cell proliferation and apoptosis analyses, inhibition of cortisol in 
krasV12-expressing males effectively reduced liver cell proliferation and apoptosis to 
levels even below those in krasV12-expressing female. Cortisol/dox double-treated 
krasV12-expressing females showed much higher cell proliferation and apoptosis, which 
were even comparable to those in krasV12-expressing males (Figure 3.11d and e). Thus, it 
is evident that the cortisol induced increase in TANs and TAMs could, at least in part, 
contribute to the significant acceleration of carcinogenesis observed in male kras+ fish.  
 
3.3.6 Gender difference in cortisol and TGFB1 level in human liver disease patients 
In human liver diseases, increased cortisol levels have been observed in morbidly 
obese patients and, though less frequently, in HCC patients (Sacerdote, Inoue, Thomas, & 
Bahtiyar, 2015; Torrecilla et al., 2012). To observe if the gender disparate cortisol levels 
and the Tgfb1 induction observed in our krasV12 HCC zebrafish model would also be 
reflected in human patients, a panel of liver disease samples, including normal, pre-HCC 
(liver inflammation and cirrhosis patients) and HCC, were analyzed for levels of 
HSD11B1, cortisol, and TGFB1. Each sample was stained by H&E for confirmation of 
their histology (Figure 3.12a) and then stained for HSD11B, cortisol and TGFB1  (Figure 
3.12b-d). HSD11B1 expression was significantly higher in both pre-HCC and HCC males 
than in female patients (Figure 3.12e). In contrast, cortisol level in liver disease patients 
















pre-HCC males (4/17) and 33% HCC male (7/21) patients had increased cortisol while 
only a single female HCC patient (out of 8) had a high cortisol level in the liver (Figure 
3.12f). Interestingly, expression of both HSD11B1 and accumulation of cortisol were 
restricted to liver sinusoids (Figure 3.12b and c), but not within hepatic plates, suggesting 
the origin of cortisol arises from non-hepatocytes. Finally, Male-dominant TGFB1 
expression was observed significantly higher in both pre-HCC and HCC samples (Figure 
3.12d and g). The levels of cortisol and TGFB1 protein showed a positive and significant 
correlation in HCC patients (R=0.76, P=0.02) (Fig. 7H), suggesting that the molecular 
mechanism of cortisol-induced TGFB1 expression is potentially translated in this cohort 
of patients. 
 
3.4 Discussion  
Previous studies on HCC gender disparity have been mainly focused on the effects of sex 
hormones because of two main reasons: 1) these hormones are produced in obvious 
gender-biased manners; 2) expression of estrogen and androgen receptors in HCC 
patients suggesting susceptibility of the diseased cells to these hormones (W. L. Ma, Lai, 
Yeh, Cai, & Chang, 2014; A. G. Wang et al., 2006). However, failure of estrogen and 
androgen related HCC clinical trials as well as inconclusive results from these clinical 
trials (Chow et al., 2011; Chow et al., 2002; Yeh et al., 2013) have suggested the 
important roles of other potential factors. For example, prolactin, a female luteotropic 
hormone, has been recently shown to confer protection in females in a Myc-induced HCC 
mouse model, indicating the potential roles of other hormones in HCC gender disparity 




In this study, we demonstrated a novel role of cortisol on promoting gender disparity in 
HCC carcinogenesis by using a combination of human liver disease clinical samples and 
a krasV12-induced zebrafish HCC model (Chew et al., 2013). Zebrafish is an ideal model 
for study of cortisol elicited effects, as both human and zebrafish utilize cortisol as their 
main stress hormone while mouse and rat make use of corticosterone instead (Egan et al., 
2009). We found a male dominant increase of cortisol synthesis in the krasV12-expressing 
livers in our zebrafish HCC model, which is in line with our human clinical studies. 
Several other independent studies have also demonstrated that cortisol is at a higher level 
in males than in females (Daughters, Gorka, Matusiewicz, & Anderson, 2013; Lippi et 
al., 2008; Van Cauter, Leproult, & Kupfer, 1996) and a high level of cortisol has been 
associated with a more aggressive breast, ovarian, cervical and lymphoma cancer 
phenotype, mediated by a cancer associated inflammation response (Schrepf et al., 2013). 
Notably, cortisol promotes liver disease progression by promoting hepatic dyslipidemia 
and increased cortisol synthesis has been observed in liver of morbidly obese patients 
(Torrecilla et al., 2012). 
 
In our current study, we demonstrated a positive correlation between cortisol and Tgfb1 
in both human and zebrafish HCC. Previous studies conducted in both fish and human 
have indicated that corticosteroids are capable of increasing circulating white blood cell 
count (Pickford, Srivastava, Slicher, & Pang, 1971; Pountain, Keogan, Hazleman, & 
Brown, 1993). In addition, glucocorticoid can increase tgfb1 expression in a variety of 
human cell lines including T-cells, fibroblasts, osteoclasts, etc. (Almawi & Irani-Hakime, 
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1998; Peltier et al., 2003). Mechanistically, glucocorticoids antagonize Tgfb specific 
RNases, thus indirectly stabilizing TGFB1 mRNA (Reyes-Moreno et al., 1995). Tgfb1 
has been shown to be a macrophage and neutrophil chemoattractant in human (Reibman 
et al., 1991; Yoshimura et al., 2006) and it is also the best known inducer of pro-
tumorigenicity of TANs and TAMs (Fridlender et al., 2009). Hence, cortisol-induced 
Tgfb1 overexpression would possibly explain for the increased infiltration of TANs and 
TAMs as well as their more vivid behavior observed in male kras+ zebrafish. Our 
morpholino knockdown experiments to suppress differentiation of neutrophils and/or 
macrophages also indicated that TANs and TAMs are pro-tumor during the initiation of 
hepatocarcinogenesis in zebrafish. This is in line with the prevailing knowledge in human 
and mouse studies that TANs and TAMs can promote tumor proliferation, angiogenesis 
and epithelial-mesenchymal transition (Shirabe et al., 2012; C. Yan et al., 2015). 
Furthermore, in human HCC, both TAN and TAM infiltrations are indicators of poor 
disease prognosis (Y. W. Li et al., 2011; Yeung et al., 2015).  
 
In conclusion, using a zebrafish HCC model and human liver disease samples, cortisol 
was shown to contribute to gender disparity in HCC carcinogenesis via Tgfb1 to initiate 
the pro-tumor responses of TANs and TAMs. This study demonstrated that hormones 
other than estrogen and androgen are not simply bystanders but may also actively 
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Nonalcoholic fatty liver disease, ranging from elevated lipid accumulation in hepatocytes 
(steatosis) to steatosis with inflammation and fibrosis, commonly referred to as 
nonalcoholic steatohepatitis (NASH)(Tiniakos et al., 2010). NASH patients are at an 
increased risk for malignancy in both hepatocyte and cholangiocyte lineage(Michelotti et 
al., 2013).  A growing number of studies have pointed to the chronic inflammation in 
NASH as the key promoter of the disease. In a mouse model with choline-deficient high-
fat diet, metabolic activation of CD8+ T cells and natural killer cells promotes NASH to 
HCC transition(Wolf et al., 2014). However, there is basically no knowledge about the 
transition of NASH to CCA (cholangiocarcinoma).  
 
One of the key inflammatory cytokines that mediate almost all stages of the liver diseases 
is transforming growth factor beta (TGFβ). In NASH, TGFβ contributes to lipid 
accumulation by deregulating lipid metabolism and enhancing apoptosis of lipid-
accumulating hepatocytes to lead to progression of NASH to fibrosis (L. Yang et al., 
2014). The activating role of TGFβ on Kupffer cells and hepatic stellate cells, which 
exacerbate liver fibrosis, is well documented (Seki et al., 2007). However, during 
carcinogenesis, the role of TGFβ remained controversial. In some mouse models with 
decreased availability of TGFβ receptor II, HCC susceptibility is greatly increased 
(Kanzler et al., 2001). However, in other studies, TGFβ promotes HCC by inducing 
hepatocyte apoptosis and compensatory proliferation(Z. Yan et al., 2015). A zebrafish 
transgenic model expressing hepatitis virus proteins in hepatocytes induces CCA, which 
was attributed to an elevated TGFβ expression(Liu et al., 2012). In contrast, 
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cholangiocyte-specific knockout of TGFβ receptor II gene in mice induces CCA, 
suggesting that TGFβ signaling restricts cholangiocyte carcinogenesis(X. Mu et al., 
2016). Thus, there is a need of understanding of molecular switches between different 
modes of TGFβ action and it is likely that the timing and duration of TGFβ signaling are 
critical in the regulation of different molecular pathways and the effect elicited(L. J. Ma 
et al., 2004; Rube et al., 2000; J. H. Sherman et al., 1993).  
 
In this study, the molecular mechanism driving disease transition from NASH to HCC 
and CCA was investigated. Through diet-induced zebrafish NASH, we found an elevated 
leptin secretion that induced tgfb1a overexpression. By generation of an inducible tgfb1a 
transgenic zebrafish model, we found that chronic, high level of hepatocyte-specific 
tgfb1a expression resultant in both HCC and CCA. By comparison of zebrafish and liver 
disease patient samples, we provided the first evidence of tgfb1 as an oncogene in liver 
carcinogenesis.  
 
4.2 Material and methods 
4.2.1 Zebrafish husbandry 
This study involving zebrafish was carried out in accordance with the recommendations 
in the Guide for the Care and Use of Laboratory Animals of the National Institutes of 
Health and the protocol was approved by the Institutional Animal Care and Use 
Committee (IACUC) of the National University of Singapore (Protocol Number: 096/12). 
Throughout the experiments, humane endpoints were used and the experimental fish were 
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euthanized prior to the defined experimental endpoints. The health of the fish was 
monitored twice a day and water quality was monitored daily. Euthanasia was conducted 
when fish showed signs of unrelieved sickness, pain and distress (e.g. inactive, 
unbalanced swimming; lack of appetite; bleeding from the gill cover and/or change of 
skin color, etc.).  
 
4.2.2 Transgenic zebrafish 
Several transgenic lines including Tg(lyz:DsRed2) (nz50Tg) with DsRed-labeled 
neutrophils under the lyz (lysozyme C) promoter(C. Hall et al., 2007), Tg(mpeg1:GFP) 
(gl22Tg) with mCherry-labeled macrophages under the mpeg1 (macrophage expressed 
gene 1) promoter(Ellett et al., 2011), and Tg(fabp10:DsRed; ela3l:EGFP) (gz15Tg) with 
DsRed-labeled hepatocytes under the fabp10a (fatty acid binding protein 10a) 
promoter(Korzh, Pan, Garcia-Lecea, Winata, Pan, et al., 2008) were used in this study 
and referred to as lyz+, mpeg+ and fabp+, respectively, in the present report.  
 
4.2.3 Generation of tgfb1a transgenic zebrafish  
Full-length tgfb1a cDNA was cloned by RT-PCR from liver RNA of WT adult zebrafish. 
Synthesis of Ac transposase RNA and microinjection were performed as previously 
described (Z. Li et al., 2013). Plasmid fabp10a-mCherry-T2A-LexPR-LexOP-tgfb1a was 
constructed for mifepristone inducible expression of tgfb1a expression. Transgenic 
founders were generated by injection of the aforementioned plasmid. 10 pg of plasmid 
DNA with 50 pg of in vitro synthesized AC transposase RNA was injected into zebrafish 
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embryos at the one-cell stage. The injected embryos were raised to adults and out-crossed 
to wild-type fish for testing germline transmission. The resulted transgenic line is named 
Tg(fabp10:mcherry-t2a-lexpr; lexop-tgf�abp1and referred to as tgfb1a+ in this report. 
 
4.2.4 Feeding with supplements 
Supplement-infused diets were prepared as previously described. Briefly, glucose 
(Sigma), fructose (Sigma), cholesterol (Sigma) was dissolved in DMSO to make 10% 
solutions, of which 400 µl was added to 0.5 g of standard zebrafish larval food. The diets 
were left to dry overnight and grounded to powder form. 5-dpf larvae fed with normal, 
10% glucose, 10% fructose or 10% cholesterol infused diet. To study cholesterol 
clearance, BODIPY® 493/503 cholesterol (Life Tech) was added directly to the water to 
1 μg/ml. For imaging fluorescent cholesterol, exposed larvae were fixed in 4% PFA for 2 
hours at room temperature, embedded in 1.5% bacto-agar and soaked in 30% sucrose 
overnight at 4°C.  The embedded larvae were then cryo-sectioned and imaged 
immediately. 
 
4.2.5 Oil Red O staining 
12-dpf (day post fertilization) larvae were fixed in 4% paraformaldehyde (PFA) (Sigma) 
in PBS at 4°C and incubated in 60% 2-propanol for 10mins, followed by staining with 
freshly filtered 0.3% Oil Red O in 60% 2-propanol. 
 
4.2.6 Isolation of hepatocytes by FACS 
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150 12-dpf fabp+ larvae per dietary plan were used for FACS using a cell sorter (BD 
Aria).  Whole larvae were dissociated into single cells using a 40-µm mesh (BD falcon) 
and enzymatically digested with 0.05% trypsin (Sigma). Hepatocytes were isolated based 
on mCherry expression. 
 
4.2.7 RNA extraction, cDNA amplification and RT-qPCR 
Total RNA was extracted using RNeasy mini kit (Qiagen). A total of 5 ng RNA was used 
as a template to synthesize and amplify cDNA using QuantiTect Whole Transcriptome 
Kit (Qiagen). Amplified cDNA was used for RT-qPCR with LightCycler 480 SYBR 
Green I Master (Roche). Interested genes were amplified by 40 cycles (95°C, 20 seconds; 
65°C, 15 seconds; 72°C, 30 seconds). The sequences of primers used are presented in 
Supplementary Table 1.  
 
4.2.8 Chemical treatments 
For chemical treatments, 5-dpf zebrafish larvae fed with 10% cholesterol-infused diet 
were co-exposed with either 1 μM of JSI124, a Stat3 inhibitor (Tocris), or LY29400, a 
PI3k inhibitor (Tocris), for 7 days.  For induction of tgfb1a expression from tgfb1a+ 
transgenic zebrafish, 1, 2 or 3 μM of mifeprisone (Sigma) were used to incubate 3-
month-old fish for 6 weeks. For inbition of Smad and Erk activity, 1 μM  PR169316 
(Sigma) or U0126 (Sigma) was added to tgfb1a+ zebrafish after 3 weeks of 3 μM 





4.2.9 Histological and cytological analyses 
10 Adult livers or 20 12-dpf larvae were fixed in 4% PFA/PBS (Sigma) and paraffin-
sectioned at 5 μm thickness using a microtome, followed by hematoxylin and eosin 
(H&E), Sirus Red, immunofluorescence (IF) or immunohistochemistry (IHC) staining. 
H&E (Sigma) and PicoSirus Red (Sigma) stainings were carried out as per 
manufacturer’s instruction. For immunofluorescence staining, antibodies used are 
presented in Supplementary Table 2. 
 
4.2.10 Photography and image analysis 
At each sampling point, 10 adult fish or 20 larvae of each group were randomly chosen 
for imaging. Adult zebrafish were anesthetized in 0.08% tricaine (Sigma) and larvae 
immobilized in 3% methylcellulose (Sigma) before imaging. Adult zebrafish was 
photographed individually with Olympus microscope. Each larva was photographed 
separately either using Olympus microscope or a confocal microscope (Carl Zeiss 
LSM510).  
 
4.2.11 Human patient sample.  
Paraffin-embedded human liver disease progression tissue microarray was purchased 
from Biomax Inc. (LV8011a). Patients were classified into five groups: Normal (n=5), 
inflammation (n=7), cirrhosis (n=16), HCC (n=30) and CCA (n=12). Four slides were 




4.2.12 Statistical analysis 
Statistical signiﬁcance between two groups was evaluated by two-tailed unpaired Student 
t-test using inStat version 5.0 for Windows. Statistical data are presented as mean 
values±standard error of mean (SEM). Throughout the text, ﬁgures, and ﬁgure legends, 
the following terminology is used to denote statistical signiﬁcance: *p<0.05 
 
4.3 Results 
4.3.1 Diet-induced NASH in zebrafish larvae stimulates tgfb1a expression  
NASH can be induced in zebrafish with a high fructose or cholesterol diet (Dai et al., 
2015; Sapp et al., 2014). 5 dpf (day postfertilization) zebrafish larvae were fed for 7 days 
with normal, 10% glucose, 10% fructose or 10% cholesterol diet. Only fructose- or 
cholesterol-diet induced a significant increase of hepatic triglyceride accumulation 
(Figure 4.1a and b). To observe if the steatotic livers had impaired ability for lipid 
clearance, larvae on different diets were co-exposed to 1 μg/ml of fluorophore-tagged 
cholesterol from 4 dpf.  Half of the exposed larvae were sacrificed at 10 dpf and 
significantly higher number fluorophore-tagged cholesterol deposits were observed in 
liver sections of fructose- and cholesterol-fed larvae (Figure 4.1c). For the remaining 
half, the fluorophore-tagged cholesterol was removed and sampled at 12 dpf. By then 
fructose-fed larvae already eliminated fluorophore-tagged cholesterol while cholesterol-
fed larvae showed lower clearance ability (Figure 4.1d). By RT-qPCR analysis, 
hepatocytes from larvae fed with fructose or cholesterol showed up-regulation of 
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lipogenic genes including srebp1, pparg and cebpa  (Figure 4.1e).  
 
Another key aspect of NASH is the initiation of chronic inflammation response. Using 
DsRed-expressing neutrophil (lyz+) and mCherry-expressing macrophage (mpeg+) 
reporter transgenic zebrafish, immune cell infiltration was examined in larvae on 
different diets. In fructose- and cholesterol-fed larvae, significant increases in neutrophil 
and macrophage densities were observed, compared to larvae on normal or glucose diet 
(Figure 4.2a and b). Staining of Nfkb2, a key inflammatory regulator of NASH, also 
showed up-regulation in fructose- and cholesterol-fed larvae (Figure 4.2c and d). 
Elevated inflammatory response in hepatocytes of fructose- and cholesterol-fed larvae 
was further proved by up-regulation of pro-inflammatory genes, il1b, tnfa and nfkb2 
(Figure 4.2e). Thus, NASH was induced in larvae within 7 days of fructose and 





















































4.3.2 NASH-induced leptin elevation induces tgfb1a overexpression 
Leptin is a satiety hormone to regulate appetite and it activates JAK/STAT3 and 
PI3K/AKT pathways(Fruhbeck, 2006). We hypothesized that the increased triglyceride 
accumulation in hepatocytes of fructose- or cholesterol-fed larvae would trigger an 
increase of leptin. Consistent with this, both leptin mRNA and protein were increased, 
correlating to the extent of NASH (Figure 4.3a and b). Leptin is also known to induce 
Tgfb1 (Cayon, Crespo, Mayorga, Guerra, & Pons-Romero, 2006). Hence, expression of 
tgfb1a mRNA and protein was also examined in larvae on different diets. Both tgfb1a 
mRNA and protein showed corresponding increases with leptin expression (Figure 4.3c 
and d). Using an inhibitor of JAK/STAT3 (JSI-124) or PI3K/AKT (LY294002) pathway, 
leptin-induced Tgfb1 expression was suppressed by JSI-124 but not LY294002 in 
cholesterol-fed larvae (Figure 4.3d). Downstream markers of Tgfb1 signaling, P-Smad2 
and P-Erk, showed corresponding increases in fructose-fed and cholesterol-fed larvae 
(Figure 4.4a and b), which were similarly inhibited by JSI-124 but not LY294002. Thus, 

















































4.3.3 Persistently high tgfb1a expression drives HCC and CCA 
TGFB1 is known to promote NASH and liver fibrosis, but its role in HCC remains 
controversia l(Kanzler et al., 2001; L. Yang et al., 2014). Both timing and level of TGFβ 
activation are suggested for its diverse effects (Rube et al., 2000; J. H. Sherman et al., 
1993). To clarify the role of Tgfb1 in liver disease progression, an inducible tgfb1a 
transgenic zebrafish line was generated using a DNA construct depicted in Figure 4.5a. 
Mifepristone was used to induce transgenic tgfb1a expression, allowing the control of 
duration and level of transgenic expression (Nguyen et al., 2012a; L. Sun et al., 2015). A 
chronic induction experiment was conducted with three dosages, 1 μM (low), 2 μM 
(medium) and 3 μM (high) of mifepristone (Figure 4.5b). 
 
By 6 weeks of chronic induction, both tgfb1a mRNA and protein showed a dose-
dependent increase while expression of mCherry mRNA and protein was rather constant 
among the different dosage groups (Fig. 4.5c and d). TGFβ receptor genes, tgfbr1a, 
tgfbr1b and tgfbr2, were also increased in hepatocytes of tgfb1a+ zebrafish under high 
induction (Figure 4.5e). Histologically, at the low induction, moderate hepatocyte 
hyperplasia and marked increase of dead hepatocytes were scattered throughout the liver. 
At the medium induction, all fish examined showed increased hepatocyte hyperplasia. 
~60% of fish had well demarcated clusters of highly vacuolated hepatocytes which 
compressed surrounding hepatic tissue, a typical feature of hepatocellular adenoma 
(HCA). At the high induction, all fish showed marked hepatic hyperplasia. Liver cells of 
most fish showed high nuclear-to-cytoplasmic ratio, with prominent and/or multiple 





















demarcation of hepatic plate. 70% fish were diagnosed as grade II HCC and the 
remaining as HCA (Figure 4.6a and b).  
 
Cytological analysis for different levels of tgfb1a induction was consistent with the 
histological observations. PCNA+ proliferating cells showed a time- and dose-dependent 
increase (Figure 4.6c). Caspase 3+ apoptotic cells were increased across all the induction 
doses at week 3. At week 6, the low tgfb1a-expressing zebrafish had the highest apoptosis 
while the medium and high tgfb1a-expressing groups showed decreased apoptosis 
(Figure 4.6d).  
 
Interestingly, after 6 weeks of high tgfb1a induction, 80% induced tgfb1a+ zebrafish had 
patches in the liver without Tgfb1a/mCherry expression (Figure 4.6c and d). Histological 
examination revealed that 30% of these fish contained focal areas of hyperplastic bile 
preductules and larger bile ducts. Another 30% fish had biliary tissues with irregular and 
poorly differentiated ductal structures that invaded through the basement membranes, a 
distinct feature of CCA (Figure 4.7a).  Co-staining of a biliary cells marker (keratin18 or 
Alcam) with a myofibroblast marker (αSma) validated these structures as bile ducts 
(Figure 4.7b). TGFβ receptor genes were up-regulated in cholangiocytes from tgfb1a+ 
zebrafish after 6 weeks of high induction (Figure 4.5f). Average circumference of bile 
ducts in the high tgfb1a-expressing fish was also significant increased (Figure 4.7c), 











































4.3.4 Role of inflammation, fibrosis and epithelial-mesenchymal transition (EMT) in 
Tgfb1a-driven carcinogenesis 
To further investigate how tgfb1a overexpression drove carcinogenesis, timing of 
activation of inflammation, fibrosis and EMT response during chronic tgfb1a induction 
was examined. Inflammatory markers including Nfkb2 (a master regulator of 
inflammation), CD4 (marking a subset of T-cells) and Csf1r (for macrophages) showed 
almost linear increases over the induction doses, with the levels at week 6 higher than 
week 3 (Figure 4.8). Hence, inflammation occurred throughout the chronic tgfb1a 
induction. Next, laminin, collagen and Sirius red staining were carried out for liver 
fibrosis. At week 3, there were dose-dependent increases while at week 6, increases of 
liver fibrosis markers were only evident at low induction dose; thus, liver fibrosis was an 
early event of tgfb1a overexpression (Figure 4.9). Lastly, E-cadherin, vimentin and β-
catenin were used to indicate EMT. The three markers were changed significantly only in 
the medium and high induction groups at week 6 with increased vimentin (mesenchymal 
marker) and decreased E-cadherin and β-catenin (epithelial marker), implying that EMT 
was a late event of tgfb1a induction (Figure 4.10). Thus, chronic induction of tgfb1a in 
hepatocytes caused persistent inflammation and liver fibrosis at early stage and likely 
carcinogenesis with indicators of EMT at late stage.  
 
4.3.5 Chronic and high tgfb1a expression induces switching in dominant signaling 
pathways 
The duration- and dose-dependent effect of tgfb1a implied an intricate molecular 


































































Erk pathways that are respectively associated with apoptosis and proliferation(Derynck & 
Zhang, 2003). To investigate if the pleiotropic effect of Tgfb1 was due to changes in the 
two pathways, co-staining of Hnf4a (demarcates hepatocytes (DeLaForest et al., 2011)) 
with P-Smad2 or P-Erk was conducted. By 3 weeks of tgfb1a induction, both P-Smad2 
and P-Erk showed dose-dependent increases, but P-Smad2+ hepatocytes had a higher 
initial increase than P-Erk+ hepatocytes, suggesting that short, low tgfb1a induction 
favored Smad pathway. By 6 weeks of tgfb1a induction, dramatic increase in P-Erk+ 
hepatocytes was observed while P-Smad2+ hepatocytes were highly increased only at the 
low induction dose. The P-Erk/P-Smad2 ratio was low at the low induction dose but 
increased dramatically at the medium and high doses (Figure 4.11a-c). By 9 weeks, P-
Smad2+ hepatocytes continued to fall with the medium induction dose while P-Erk+ 
hepatocytes increased persistently (Figure 4.11a-c), suggesting the switch in dominance 
between Smad and Erk pathways was affected not only by the level but also duration of 
Tgfb1 signaling.  
 
To investigate if aberrant Smad and Erk pathways contributed to oncogenicity of Tgfb1, 
tgfb1a+ fish were induced with the high mifepristone dose for 3 weeks and inhibitor of 
Smad2 (PD169316) or Erk (U0126) was added for another 3 weeks. PD169316 did not 
relieve HCC histology but deterred CCA and reduced bile duct hyperplasia in tgfb1a+ 
zebrafish. In contrast, in the presence of U0126, tgfb1a+ zebrafish had less severe hepatic 
neoplastic features, with 10% of the fish with HCC, 20% with HCA and the rest with 
hyperplasia, in comparison with 60% HCC, 20% HCA and 20% hyperplasia in the group 
























dependent mechanism while CCA formation could be attributed to activation of both 
Smad and Erk. Molecularly, inhibition of Smad did not significantly increase P-Erk+ 
hepatocytes while Erk inhibition caused P-Smad2+ hepatocytes to regain dominance 
(Figure 4.12b, c and f). Consistent with the histological findings, Smad inhibition 
increased cell proliferation and decreased apoptosis while Erk inhibition had opposing 
effect (Figure 4.12d, e and g).  
 
To examine the molecular effect of chronically high Tgfb1 induction in cholangiocytes, 
co-staining of Keratin18 with P-Smad2 or P-Erk was performed (Figure 4.13a, b). By 6 
weeks of high tgfb1a induction, cholangiocytes showed significant increases of both P-
Smad2+ and P-Erk+. Inhibition of Smad or Erk also decreased P-Smad2+ or P-Erk+ in 
cholangiocytes accordingly.  
 
Erk phosphorylates Smad2 in the linker domain (Serine 245/250/255), inhibiting both 
Smad2 nuclear localization and its anti-mitogenic function (Hough, Radu, & Dore, 2012). 
To understand the switch between Smad and Erk, co-staining of P-Erk and P-Smad2L 
(linker phosphorylation) was carried out. By medium or high tgfb1a induction, P-Erk+/P-
Smad2L+ cells were significantly higher at week 6 than at week 3, which was greatly 
reduced by PD169316 but not U0126; thus, chronic tgfb1a induction resulted in 
phosphorylation of Smad2 linker via an Erk-dependent mechanism (Figure 4.14a). 
Furthermore, localization of P-Smad2L was observed in hepatocytes but not 
cholangiocytes after 6 weeks of tgfb1a induction, thus consistent with the co-activation of 

























































pathway is commonly associated with apoptosis while Erk pathway is synonymous with 
cell proliferation(Derynck & Zhang, 2003),  to investigate if the decreased P-Smad2+ 
hepatocytes were due to apoptosis death while increased Erk+ hepatocytes were a result 
of overwhelming cell proliferation, co-staining of P-Erk/PCNA as well as P-
Smad2/Caspase 3 was carried out. With 6 weeks of tgfb1a induction, both P-
Erk+/PCNA+ and P-Smad2+/Caspase3+ cells showed dose- and duration-dependent 
increases (Figure 4.15a and b). Neither PD169316 nor U0126 treatment could decrease 
the proliferating P-Erk+ cells or apoptotic P-Smad2+ cells, suggesting the dependency of 
tgfb1a induction for the increased double-positive cells.  
 
4.3.6 Conserved expression patterns of TGFβ, SMAD and ERK in human liver disease 
patients  
In several independent transcriptomic analyses of NASH, cirrhosis and HCC in human, 
TGFB1 was consistently up-regulated (Cayon et al., 2006; Hoshida et al., 2009; Sanchez-
Antolin et al., 2015). However, a lack of coherent study across different stages of the 
liver disease on TGFB1 expression and its downstream activation hindered the 
understanding of the chronical effect of TGFB1. In this study, liver samples from human 
patients (normal, n=5; inflammation, n=7; cirrhotic, n=16; HCC, n=30) were examined 
for TGFB1, P-SMAD2 and P-ERK expression. As shown in Figure 4.16a and b, 
percentages of TGFB1+, P-SMAD2+ and P-ERK+ cells were all increased progressively 
across the liver disease spectrum. In particular, 26% of HCC samples showed 
significantly higher TGFB1 expression, consistent with the transcriptomic data in which 































Interestingly, correlation between TGFB1 and P-SMAD2 was decreased with liver 
disease progression (inflammation, R=0.9615, P=0.0005; cirrhosis, R=0.8862, P<0.0001; 
HCC R=-0.2113, P=0.2624) while correlation between TGFB1 and P-ERK showed the 
opposite trend (inflammation, R=0.2043, P=0.6603; cirrhosis R=0.4047, P=0.1200; HCC 
R=-0.5097, P=0.0040) (Figure 4.17a and b). Thus, in HCC patients with high TGFB1 
expression, the dominant pathway was ERK instead of SMAD (Figure 4.17a and b), 
consistent with observations in tgfb1a+ zebrafish. By comparing normal bile ducts and 
CCA samples for expression of TGFB1, P-SMAD2 and P-ERK, there were consistent 
increases in expression of all three proteins (Figure 4.18a and b); thus, up-regulated 




NASH in human is characterized by both increased fat accumulation and chronic 
inflammatory response in the liver(Hashimoto et al., 2013). In this study, through feeding 
of high fructose- or cholesterol-infused diet, zebrafish larvae showed rapid triglyceride 
accumulation in the liver, impaired ability of hepatic cholesterol clearance and elevated 
inflammatory response, thus recapitulating key characteristics of human 
NASH(Hashimoto et al., 2013; Michelotti et al., 2013; Wolf et al., 2014). Molecularly, 
hepatocytes of these zebrafish larvae showed marked increases of leptin and Tgfb1. 
Similarly in humans, numerous studies have shown a rise of serum leptin in NASH 
patients(Chitturi et al., 2002; Uygun et al., 2000). A transcriptomic study of NASH also 






























































expression, supporting the connection of leptin pathway and TGFB1 overexpression in 
NASH(Cayon et al., 2006). 
 
In our study on human liver disease progression, TGFB1 and its downstream SMAD and 
ERK pathways were significantly activated with the advancement of liver disease to 
HCC. In particular, 26% of HCC patients showed drastic increase in TGFB1 expression, 
consistent with a previous transcriptomic report on HCC patients(Giannelli et al., 2014). 
Interestingly, the correlation of TGFB1 and P-SMAD2 is high for inflammation and 
cirrhosis while the correlation of TGF�1 and P-ERK is high in HCC (Fig. 6c), implying 
that chronic, high TGFB1 expression in human livers also shifts the dominant 
downstream pathway from SMAD to ERK, consistent with previous reports in human 
cell lines that increased transgenic TGFB1 expression induced a shift from canonical 
(SMAD) to non-canonical pathway (ERK, AKT, etc.)(Derynck & Zhang, 2003; Dzieran 
et al., 2013; Hayashida, Decaestecker, & Schnaper, 2003; Hough et al., 2012; Y. Mu, 
Gudey, & Landstrom, 2012). Our tgfb1a+ transgenic zebrafish model recapitulated the 
switch between SMAD and ERK signaling as six weeks of chronic, high tgfb1a induction 
caused a sharp decrease of P-Smad2+ hepatocytes and a corresponding increase of P-
Erk+ hepatocytes, eventually leading to HCC via an Erk-dependent mechanism. This 
switch in dominant pathway can be attributed to two possible mechanisms. First, Tgf1a-
induced Erk-activation resulted in inactivating linker phosphorylation of Smad2, which 
occurred only after 6 weeks of medium or high Tgfb1a induction, suggesting that 
persistently high Erk signaling is essential for Smad2 linker phosphorylation. A high 
Smad2 linker phosphorylation had been reported to contribute significantly to liver 
120 
 
fibrosis and also carcinogenesis of other cell types, such as colon rectal cancer and 
melanoma(Cohen-Solal et al., 2011; Matsuzaki, 2011; Shang et al., 2012).  Second, co-
localization of PCNA+/P-Erk+ and Caspase3+P-Smad2+ was increased with dose and 
duration of Tgfb1a induction; thus, in Tgfb1a-induced carcinogenesis, P-Smad2+ cells 
undergo apoptosis while P-Erk+ cells proliferate, tilting the balance between the two cell 
populations. Interestingly, in a mouse study, hepatocyte-specific induction of Tgfb1 
expression caused liver fibrosis but not HCC(Ueberham et al., 2003). The relatively 
relaxed phenotype observed could be due to the intermittent induction of Tgfb1 in these 
transgenic mice, in contrast to the persistently long-term induction in our tgfb1a+ 
zebrafish.  
 
Curiously, by chronic and high tgfb1a expression, 40% of the fish developed bile duct 
hyperplasia and another 30% had mixed HCC-CCA. Thus, hepatocyte-specific 
expression of tgfb1a drives not only HCC but also CCA. This is reminiscent of a 
previously reported zebrafish CCA model by hepatocyte-specific expression of two 
hepatitis virus proteins, in which transcriptomic study of the CCA detected a prominent 
increase of Tgfβ signaling(Liu et al., 2012). In our study, biliary cells in zebrafish and 
human have similarly concurrent activation of Erk and Smad pathways; this is in 
consistency with genomic analyses of CCA patients, in which MAPK and SMAD 
signaling have been identified as most commonly affected mutations(Ong et al., 2012). In 
our zebrafish model, inhibition of either pathway deterred CCA, suggesting simultaneous 
activation of the two signalings is essential for tgfb1a-induced CCA. Interestingly, Tgfb1 
has been reported to have a restrictive role in bile duct growth as hepatocyte-specific 
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knockout of Tgfbr2 in a mouse Pten-/- HCC model induced robust cholangiocyte 
proliferation(X. Mu et al., 2016). This is in fact consistent with our study. The chronic 
and high tgfb1a expression depleted Smad signaling below the basal level in hepatocytes, 



























TGFB1 is a multi-functional, pleiotropic molecule that exerts its effect in almost all 
stages of liver cancer. In this project, through a tripartite study, using a combination of 
transgenic zebrafish model and human liver disease clinical samples, we established the 
pro-tumor role of Tgfb1 not only in the context of orchestrating tumor microvironment to 
promote hepatocarcinogenesis but  also as a novel oncogene as its overexpression of 
Tgfb1 alone can cause both HCC and CCA.  
 
In the first study, the interaction of neutrophils and oncogenic hepatocytes in 
hepatocarcinogenesis was investigated. We observed a rapid recruitment of neutrophils 
into oncogenic liver, lending to accelerate tumor progression. Molecular analyses of 
FACS-isolated hepatocytes and TANs indicated changes of several important molecular 
pathways, including promotion of a pro-inflammatory microenvironment in oncogenic 
hepatocytes and decreases of anti-tumor in TANs. Thus, our data suggest a promoting 
role of neutrophils in early hepatocarcinogenesis. 
 
In the second study, with a combination of clinical liver disease samples and a krasV12-
expressing zebrafish HCC model, we found that male transgenic zebrafish showed 
accelerated carcinogenesis as compared to female counterparts. Interestingly, cortisol was 
highly produced in males and it contributed to enhanced infiltration of tumor associated 
neutrophils (TANs) and TAMs in male oncogenic liver. Consequently, the pro-tumor 




In the final study, the molecular mechanism for disease transition from NASH to HCC 
and CCA was investigated. Through diet-induced zebrafish NASH, we found an elevated 
leptin secretion that induced tgfb1a overexpression. By generation of an inducible tgfb1a 
transgenic zebrafish model, we found that chronic, high level of hepatocyte-specific 
tgfb1a expression resulted in both HCC and CCA. By comparison of zebrafish and liver 
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